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ABSTRACT 
Brain-Derived Neurotrophic Factor (BDNF) expression is elevated after 
status epilepticus (SE), leading to rapid activation of multiple signaling pathways, 
including the Signal Transducer and Activator of Transcription 3 (STAT3) 
pathway that mediates a decrease in GABAA receptor α1 subunit expression in 
hippocampus (Lund et al., 2008). While BDNF can signal via its pro- or mature 
form, the relative contribution of these forms to signaling after SE is not fully 
known. In the current study, induce SE in C57BL/6J mice. A thorough review of 
temporal lobe epilepsy models is reported with special emphasis on models 
useful in C57BL/6J mice. Animals in the current study underwent repetitive low 
dose pilocarpine (RLDP) to induce SE. Development of intrahippocampal kainic 
acid induced SE was also initiated to decrease mortality and increase 
effectiveness of SE when compared to RLDP. I also investigate the relative 
change in the expression of proBDNF and mBDNF after SE using BDNF-epitope 
tagged knock-in mice. In contrast to previous reports (Unsain et al., 2008; 
Volosin et al., 2008; VonDran et al., 2014), our studies found that levels of 
proBDNF in hippocampus are markedly elevated as early as three hours after SE 
onset and remain elevated for 24 hours, with no increase in mBDNF levels 
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detected. Immunohistochemistry studies indicate that seizure-induced BDNF 
increases occur in all hippocampal subfields, predominantly in principal neurons 
but also in astrocytes.  Analysis of the proteolytic machinery that acts on 
proBDNF to produce mBDNF demonstrated that acutely after SE, there is a 
decrease in tissue plasminogen activator (tPA), part of the extracellular 
proteolytic cascade, and an increase in plasminogen activator inhibitor-1 (PAI-1), 
an inhibitor of extracellular and intracellular cleavage.  These findings suggest 
that proBDNF increases rapidly following SE, likely due to both increased 
synthesis and reduced cleavage into mBDNF, and that proBDNF may be the 
initial neurotrophin signal driving intracellular signaling during the acute phase of 
epileptogenesis. 
The form and content of this abstract are approved. I recommend its 
publication. 
Approved: Amy R. Brooks-Kayal 
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CHAPTER I 
EPILEPSY MODELS AND PATHOLOGY1 
Significance 
Approximately 4.3 million adults (1.8 percent of the population) and 
approximately 750,000 children (0-17 years of age) live with active epilepsy in 
the U.S. (CDC, 2015). One in 26 people will be diagnosed with epilepsy at some 
point in their lives (Institute of Medicine (US) Committee on the Public Health 
Dimensions of the Epilepsies, 2012). Based on 2015 population figures, the 
estimated annual cost of epilepsy approaches $15.5 billion in medical costs and 
lost or reduced wages and productivity (Begley et al., 2000). Children are 
particularly at high risk for seizures, and in any given year, five out of every 1,000 
children will develop epilepsy. Known risk factors can account for only 25-45 
percent of cases of early life epilepsy, including congenital malformations of the 
central nervous system (CNS), moderate to severe head trauma, CNS infections, 
hypoxic-ischemic encephalopathy (HIE), inherited metabolic conditions, and 
genetic predispositions (Cowan, 2002).  
Although epilepsy is defined by the presence of recurrent seizures, 
epilepsy is often associated with cognitive or behavioral dysfunction, particularly 
in children, who have a 30 percent prevalence of co-morbid autism and/or 
intellectual or developmental disabilities (Nolan et al., 2003; Tuchman et al., 
                                                          
1 A portion of this chapter was previously reported in: Thomas, A. X., & Brooks-
Kayal, A. R. (2013). Excitation-Inhibition Epilepsies. In J. L. R. Rubenstein & P. 
Rakic (Eds.), Neural Circuit Development and Function in the Heathy and 
Diseased Brain (pp. 709–730). San Diego: Elsevier. doi:10.1016/B978-0-12-
397267-5.00042-X 
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2009). Children with epilepsy have higher rates of Attention Deficit Hyperactivity 
Disorder (ADHD), learning disorders, and behavioral problems, as well as 
depression and anxiety (Beghi et al., 2006; Dunn et al., 2002; Gonzalez-Heydrich 
et al., 2007; Jones et al., 2007; Laurent and Arzimanoglou, 2006).  A number of 
well-known genetic disorders share epilepsy, intellectual disability and autism as 
prominent phenotypic features, including tuberous sclerosis, Rett syndrome, 
Fragile X syndrome, Angelman’s syndrome, and genetic disorders of cortical 
development/migration such as aristaless-related homeobox gene (ARX), 
neuronal migration protein doublecortin (DCX), and lissencephaly 1 (LIS1) 
(reviewed in Brooks-Kayal, 2011; Deonna and Roulet, 2006; Guzzetta, 2006; 
Wolff et al., 2006). Approximately 30 percent of children with autism have 
epilepsy and 30 percent of children seen in tertiary epilepsy clinic have autism 
(Tuchman and Rapin, 2002; Clarke et al., 2005). Seizures themselves, 
particularly when occurring during early life, may also produce a variety of 
cellular and molecular changes in the hippocampus that may also contribute to 
an increased risk of cognitive or behavioral dysfunction (reviewed in Brooks-
Kayal, 2011).  Co-morbid changes can be progressive, over periods of years to 
over an entire life span, and their severity has been correlated with age of onset, 
seizure frequency including total number of seizures, and increasing age (Dam, 
1990; Hermann et al., 2003; Hermann et al., 2002). 
To begin the discussion on research in epilepsy, it is important to define 
the terms epilepsy and epileptogenesis. Epilepsy is a neurological disorder that is 
characterized by recurrent spontaneous seizures. Epileptogenesis is defined as 
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the process during which changes occur in the brain following a precipitating 
injury or insult that results in the development of spontaneous recurrent seizure 
activity, or epilepsy. The time period between the initial insult and the onset of 
epilepsy is referred to as the latent period. Much of the research in epilepsy is 
focused on understanding the underlying molecular mechanisms associated with 
epileptogenesis. It is important to elucidate the underlying mechanisms of 
epileptogenesis to identify better treatments of existing epilepsy, and to develop 
new therapies to prevent epilepsy, as well as the associated neurocognitive 
disorders that afflict many individuals with epilepsy (LaFrance et al., 2008).  
Epilepsy Research Benchmarks 
Every seven years experts in the field of epilepsy set forth new epilepsy 
research benchmarks during the National Institute of Neurological Disorders and 
Stroke (NINDS)-sponsored conference, “Curing the Epilepsies,” the most recent 
of which took place on April 17-19, 2013 where the 2014 NINDS Benchmarks for 
Epilepsy Research were developed. The four major benchmarks were as follows: 
I. Understand the causes of the epilepsies and epilepsy-related neurologic, 
psychiatric, and somatic conditions.  
II. Prevent epilepsy and its progression.  
III. Improve treatment options for controlling seizures and epilepsy-related 
conditions without side effects.  
IV. Limit or prevent adverse consequences of seizures and their treatment 
across the lifespan. 
The goal of these studies focuses on elucidating specific signaling 
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pathways that may contribute to epileptogenesis thereby addressing benchmarks 
I, II and III. A deeper understanding of the various signaling pathways that are 
activated during epileptogenesis may provide insight into more effective targets 
for therapeutic intervention.  
Experimental Models of Epilepsy 
Epilepsy is a very complex disease with many different etiologies and 
pathologies; therefore, it is important to develop research models that try to 
mimic the various types of human epilepsies. Animal models of epilepsy provide 
researchers the ability to utilize various biochemical, electrophysiological, and 
anatomical techniques to understand the mechanisms of epileptogenesis. One 
must choose an animal model of epilepsy that is appropriate for the research 
question posed. The following discussion will focus on animal models of temporal 
lobe epilepsy since model selection and development was an essential 
component of performing the studies presented herein. The neuropathological 
findings associated with human TLE patients include hippocampal sclerosis 
(Sommer, 1880; Margerison and Corsellis, 1966) as well as synaptic 
reorganization of the dentate granule cells (de Lanerolle et al., 1989; Sutula et 
al., 1989; Houser et al., 1990). Approximately 60 percent of TLE patients have 
neuronal loss of CA1, CA4, and hilar neurons whereas CA2 and the dentate 
gyrus appear to be resistant (Sommer, 1880; Margerison and Corsellis, 1966; 
Blümcke et al., 1999). There are several ways to categorize the different models 
of TLE, the following discussion will categorize the various models by injury 
modality. Some models commonly referred to as developmental models utilize an 
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injury early during development with spontaneous seizures developing later in 
life. Adult models of TLE utilize an injury sustained in adulthood with 
spontaneous seizures occurring after the injury.  
Environmental, Perfusion and Toxin Models 
Hypoxia 
The most common cause of neonatal seizures is HIE (Aicardi and 
Chevrie, 1970; Hauser et al., 1993). The neonatal rodent hypoxia model has 
been utilized to elucidate how global hypoxia in neonates leads to increased 
susceptibility to seizures later in life. The mechanism of epileptogenesis in this 
model has been associated with transient dysregulation of expression and 
function of AMPAR subunits (Sanchez et al., 2001, 2005; Rakhade et al., 2011). 
Humans and rodents have a similar age-dependent susceptibility to hypoxia-
induced seizures early in life, which can cause long-term susceptibility to seizure 
and neuronal death. P9-P12 Long-Evans rats demonstrate a high susceptibility to 
hypoxia-induced seizures peaking in P10 pups. Sprague-Dawley rats exhibit 
peak seizures at P8-P9 (Owens et al., 1997). Similar windows of susceptibility 
are also seen in mice.  
The hypoxia model uses a brief fifteen-minute exposure to a graded global 
hypoxia (7 to 4 percent O2, with 21 percent O2 being the percentage in normal 
room air) by altering the levels of O2 and N2 in an airtight chamber. The acute 
hypoxia-induced seizures lead to long-term increased susceptibility to seizures 
that is usually ascertained through the use of threshold doses of various 
chemoconvulsants, including pentylenetetrazol (PTZ), flurothyl and kainic acid 
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(Jensen et al., 1992), as well as to spontaneous seizures in 94.4 percent of 
animals during isolated recording sessions (Rakhade et al., 2011). 
Hypoxic Ischemia 
Neonatal seizures also occur after HIE and perinatal stroke modeled by 
the hypoxic-ischemia rodent model of neonatal seizures. This model entails 
ligation of a cerebral artery of P3-P14 rodents, usually a unilateral carotid or 
middle cerebral artery. After ligation, the rodents are allowed to recover and are 
then subjected to 15-120 minutes of hypoxia (8 percent O2) (Rice et al., 1981; 
Jensen et al., 1994; Vannucci et al., 1999). Similar to the hypoxia model, the 
hypoxic-ischemia model results in long-term increases in seizure susceptibility, 
as assessed by injections of chemoconvulsants, and in the emergence of 
epilepsy later in life (Wirrell et al., 2001; Yager et al., 2002). Approximately 56 
percent of hypoxic-ischemia treated rats go on to develop spontaneous seizures. 
All of the rats that exhibited spontaneous seizures had clearly identifiable 
infarcts; however, animals that did not develop spontaneous seizures had no 
obvious microscopic damage (Kadam et al., 2010). C57BL/6 mice subjected to a 
similar injury produced a significantly lower incidence of spontaneous motor 
seizures with only 2 out of 23 mice developing spontaneous seizures chronically 
(Peng et al., 2015). 
Hyperthermia 
The most common type of seizures in infants and young children is febrile 
seizures, with a prevalence of 2.3-4 percent of the population.  Simple febrile 
seizures are short, generalized, and occur during periods of high fevers in infants 
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and young children 3 months to 5 years of age, with a peak incidence between 6 
months and 2 years of age. Complex febrile seizures are prolonged or focal 
seizures or seizures that recur within a single febrile episode. Although the 
majority of simple febrile seizures are benign, complex prolonged febrile seizures 
have been associated with an increased risk of developing epilepsy later in life 
(Hauser, 1994; Cowan, 2002). The model for prolonged febrile seizures was first 
developed in the immature rat (Toth et al., 1998; Baram et al., 1997) and then 
adapted for mice (Dubé et al., 2005). The febrile seizure model induces 
hyperthermia to produce prolonged seizures. The core temperature of P10-11 
rats or P14-15 mice is increased gradually and maintained at hyperthermia (40-
42°C) for thirty minutes with the animal’s core temperature being tightly 
regulated. The rodents are then allowed to recover for one hour.  In this model, 
24 percent of rats go on to develop spontaneous temporal lobe seizures in 
adulthood. If the duration of hyperthermia is increased to 64 minutes then 45 
percent of rats develop spontaneous seizures in adulthood (Dubé et al., 2010). 
This model does not exhibit hippocampal neuronal loss as seen in other models 
of TLE, but does possess mossy fiber sprouting (Jiang et al., 1999; Bender et al., 
2003; Dubé et al., 2006, 2010b). The C57BL/6J strain of mice are particularly 
sensitive to hyperthermia-induced seizures (Van Gassen et al., 2008).  
Traumatic Brain Injury 
 Chronic spontaneous seizures have been observed in the fluid percussion 
and controlled cortical impact (CCI) models. Lateral fluid percussion (LFP) 
produces both focal and diffuse brain injury with focal contusions, tissue tears, 
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traumatic axonal injury, petechial intraparenchymal and subarachnoid 
hemorrhages. Spontaneous recurrent seizures are observed in 50 percent of the 
Sprague-Dawley rats undergoing LFP over a period of 12 months. The CCI 
model produces a focal brain insult to the lateral cortex and is consistent with 
intraparenchymal petechial hemorrhages that are accompanied by epidural and 
subdural hematomas. There is widespread damage to the gray matter and the 
adjacent white matter. Degeneration is observed in the cortex, hippocampus, and 
thalamus. Anywhere from 13-50 percent of animals go on to develop 
spontaneous recurrent seizures depending on the severity of injury, strain, and 
length of monitoring (Pitkänen and Immonen, 2014).  
Tetanus Toxin 
The ability of tetanus toxin to induce chronic epilepsy was first described 
in 1898 by Roux and Borrel (Roux and Borrel, 1898). The modern form of the 
tetanus toxin model of epilepsy involves stereotaxic injection of minute amounts 
of tetanus toxin into the brain to create an epileptic focus that spontaneously 
discharges. After intrahippocampal infusion of tetanus toxin in P10 rats, one to 
seven seizures are observed during the first week with each seizure lasting from 
a few seconds to several minutes. The seizure frequency usually peaks on day 
two and declines over the week following infusion (Benke & Swann, 2004). When 
the immature rats become adults, at least 50 percent of animals exhibit 
unprovoked seizures with a low prevalence (Lee et al., 1995). Tetanus toxin 
preferentially blocks release of inhibitory neurotransmitters, mainly GABA and 
glycine (Bergey et al., 1983, 1986; Williamson et al., 1992). Therefore, inhibition 
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is reduced by injecting tetanus toxin into the hippocampus of rats (Mellanby et 
al., 1984; Jefferys and Williams, 1987). 
Status Epilepticus 
Pilocarpine 
The pilocarpine-induced status epilepticus (SE) model in rats may be the 
most widely used model of temporal lobe epilepsy (TLE). Typically adult rats are 
pretreated with either 1-2 mg/kg i.p. scopolamine or 5mg/kg i.p atropine 
methylbromide to block the peripheral effects of cholinergic activation followed by 
a high dose of pilocarpine typically around 380 mg/kg i.p.. Behavioral seizures 
typically develop within 20-30 minutes. SE is typically attenuated with 
anticonvulsants, usually diazepam, to reduce mortality. After a latent period of a 
few weeks, over 90 percent of the post-SE rats develop spontaneous recurrent 
seizures for life (Priel et al., 1996). The mechanism of SE induction is associated 
with pilocarpine-mediated activation of M1 muscarinic receptors (Hamilton et al., 
1997). Activation of M1 muscarinic receptors lead to activation of phospholipase 
C and production of diacylglycerol and inositol triphosphate (IP3) which results in 
alterations in Ca2+ and K+ current thereby increasing excitability in the brain 
(Segal, 1988). The increased excitability may be due to ATPase dysfunction in 
the hippocampus, which could lead to deficient repolarization of the plasma 
membrane thereby attenuating Ca2+ extrusion (Fernandes et al., 1996; Funke et 
al., 2003). The increased levels of intracellular Ca2+ leads to glutamate release 
inducing SE.  
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Lithium Pilocarpine 
The lithium pilocarpine model is a variation of the pilocarpine model used 
most commonly in immature rodents. Systemic activation of the cholinergic 
system in lithium-treated rats induces seizures (Honchar et al., 1983). Typically, 
lithium is administered 24 hours before administration of pilocarpine. The 
pretreatment with lithium greatly decreases the amount of pilocarpine needed to 
induce SE. There are two dosing regimens, the first with a high dose of 
pilocarpine (25-60mg/kg) administered 24 hours after lithium treatment and the 
other with divided doses (10mg/kg) administered 24 hours after lithium treatment 
every 30 minutes until SE is induced (Glien et al., 2001). In P12 rats, 25 percent 
of the rats experience spontaneous electrographic seizures of limbic onset (i.e. 
TLE three months after SE (Kubová et al., 2004). In P20 rats, this percentage 
increases to 67 percent (Raol et al., 2003). 
Kainic Acid 
The seizure-inducing properties of kainic acid were first reported in 1978 
(Nadler et al., 1978). The kainic acid model is another useful model of TLE since 
after injection with kainic acid, rats >P20 experience an episode of SE hours later 
followed by days to weeks of a seizure-free latent period finally ending with 
progressive recurrent spontaneous seizures. Ninety-three percent of rats 
administered kainic acid undergo SE with 45-59 percent of injected rats 
developing spontaneous seizures with a latency of approximately 4.8 weeks 
(Stafstrom et al., 1992; Mascott et al., 1994). Spontaneous recurrent seizures do 
not develop in younger rats, since kainic acid administration to P0 and P5 rats 
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does not lead to development of spontaneous seizures (Stafstrom et al., 1992). 
There are two main dosing regimens for kainic acid-induced SE, one using a 
single high dose (Meier et al., 1992) and the other using repetitive low doses 
(Meier & Dudek, 1996).  
Electrically-induced Status Epilepticus 
 In addition to chemoconvulsant induction of SE, electrical stimulation of 
the amygdala (McIntyre et al., 1982; Nissinen et al., 2000, 2001; Pitkänen et al., 
2000; Brandt et al., 2003), the hippocampus (Lothman et al., 1989), or its 
afferents (Sloviter and Damiano, 1981; Sloviter, 1983; Vicedomini and Nadler, 
1987; Mazarati et al., 1999; Matzen et al., 2008) can be used to initiate SE.  In 
the case of hippocampal stimulation, adult rats are implanted with stimulating 
electrodes in the hippocampus. One week later, unanesthetized rats were 
stimulated with 1 ms pulses at 400 μA and 50 Hz—a train of stimuli is on for 10 s 
and off for 1 s—that continued for 90 min. Of the animals that received 
stimulation, 90 percent developed self-sustaining SE that lasted for at least 30 
minutes up to 6-12 hours in some cases. Of the animals that experienced at least 
6 hours of self-sustained SE, 80-90 percent of the animals went on to develop 
spontaneous seizures (Bertram and Cornett, 1993; Mangan and Bertram, 1998). 
In the case of hippocampal afferent stimulation, anesthetized adult rats are 
stimulated with 0.2 to 0.4 ms monophasic rectangular pulses at 20-Hz with 10 s 
train duration at 30 s intervals through chronically implanted electrodes in angular 
bundles or fimbria (Vicedomini and Nadler, 1987). All of the animals that received 
30 min of perforant path stimulation experienced approximately 4 hours of self-
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sustained SE and went on to develop spontaneous seizures (Mazarati et al., 
1999). The amygdalar stimulation paradigm utilizes a 100 ms train of 1 ms with 
60 Hz bipolar pulses at 400 μA every 0.5 s for a period of 20-30 min. Eighty-
seven percent of all stimulated animals develop self-sustained SE lasting 6-12 
hours with spontaneous seizures developing in all of the animals that underwent 
self-sustained SE (Nissinen et al., 2000).  
Influence of Age and Strain on Response to Epileptogenic Injury 
In rodents, age, strain, and modality affect the animal’s response to 
epileptogenic injury (Table 1.1). Aged rats (24 months old) are less vulnerable to 
kainic acid-induced excitotoxicity than are 3- to 20-month old rats (Kesslak et al., 
1995). Juvenile rats (P35-40) have more consistent behavioral seizures and are 
more sensitive to kainic acid than are adult rats (P70-90) (Golden et al., 1995). 
When young (<P25) rats are subjected to the same pilocarpine or kainic acid 
treatment regimens as adults, they develop acute seizures, but do not exhibit 
hippocampal neuronal loss and synaptic reorganization as in adults, nor do they 
go on to develop spontaneous recurrent seizures (Priel et al., 1996; Yang et al., 
1998; Haas et al., 2001). In rats undergoing self-sustained SE by perforant path 
stimulation, 100 percent of P35 mice developed spontaneous seizures, whereas 
11 percent of P21 mice developed spontaneous seizures (Sankar et al., 2000b). 
Percent mortality correlates significantly with age in pilocarpine-induced SE in 
rats, with a significant increase in mortality from 10 to 15 weeks of age (Blair et 
al., 2009). These findings indicate that using P35-60 rodents for SE models will 
reduce mortality and improve consistency.   
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Table 1.1. Summary of animal models of TLE.  
 
Model Basic administration
Mechanism of 
action
Pros Cons
Hippocampal 
neuronal 
loss
Granule cell 
synaptic 
reorganization
Spontaneous 
Seizures References
Adult Kainic acid (P20-Adult) High or repeated doses of KA 
administered i.p., i.v., or 
directly to brain
Induces SE Changes mimic human MTLE: 
CA1 and CA3 neuron loss 
Aberrant MF sprouting, 
astrogliosis and microgliosis.
High mortaltity rate with 
higher doses; source of 
damage drug toxicity or 
seizure activity?
++ ++ ++ Nadler et al., 1978; 
Stafstrom et al., 1992; 
Meier et al., 1992; 
Mascott et al., 1994; 
Meier & Dudek, 1996)
Lithium Pilocarpine Lithium administered i.p. 24hr 
before i.p. pilocarpine
Induces SE Very low mortality rate Utilizes lithium to potentiate 
the effects of pilocarpine
± ± + Glien et al., 2001; 
Kubová et al., 2004; Raol 
et al., 2003
Pilocarpine Administered with lithium 
either i.p. or directly
Induces SE Changes mimic human MTLE. Lesions are more prominent 
in the neocortex.
++ ++ ++ Turski et al., 1984; Priel 
et al., 1996; Cavalheiro 
et al., 1996
Electrical stimulation Electrial pulse trains 
administered to specific brain 
areas to produce self-
sustaining seizures
Induces SE Can be either unilateral or 
bilateral; changes mimic 
human MTLE.
Special equipment and time 
requirements for electrode 
implantation.
+ + ++ Amygdala (McIntyre et 
al., 1982; Nissinen et al., 
2000, 2001; Pitkänen et 
al., 2000; Brandt et al., 
2003), the hippocampus 
(Lothman et al., 1989), or 
its afferents (Sloviter and 
Damiano, 1981; Sloviter, 
1983; Vicedomini and 
Nadler, 1987; Mazarati et 
al., 1999; Matzen et al., 
2008)
Tetanus toxin Sterotaxic administration into 
brain
Blocks 
neurotransmitter 
release
Causes spontaneous motor 
seizures.
Weak or temporary seizures; 
lesions differ from human 
MTLE; limited information on 
the model.
± ± + (transient) Lee et al., 1995; Benke & 
Swann, 2004
Hyperthermia Rats 1–2 weeks old are 
subjected to ambient 
hyperthermia, heated air 
stream, or microwaves to 
induce hyperthermia
Hyperthermia leads to 
febrile convulstions in 
young rats
Attempts to mimic febrile 
convulsions that are often part 
of TLE patient histories.
Few neuropathologic 
changes occur including no 
hippocampal neuronal death.
- ± + Toth et al., 1998; Baram 
et al., 1997; Dubé et al., 
2005; Dubé et al., 2010
Traumatic Brain Injury Injury is induced by exposing 
the dura and using a fluid 
percussion instrument to 
deliver a traumatic force
Lesion formation leads 
to cellular changes
Produces spontaneous 
seizures; useful for studying 
post-TBI epilepsy.
Seizures originate from 
frontal-parietal cortex and 
progress to mesial temporal 
cortex; damage and seizure 
generation are highly 
heterogenic.
+ + ± Pitkänen and Immonen, 
2014
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In addition, rodents subjected to pilocarpine induced SE exhibit robust 
hippocampal neuronal loss, granule cell synaptic reorganization, and 
spontaneous seizures which are all hallmarks of human TLE supporting its use 
as a compelling model of human TLE.   
Seizure Induced Changes in the Brain 
Many biochemical and anatomical changes occur in the brain after an 
epileptogenic injury. Much of the research in epilepsy is focused on 
understanding those changes and identifying specific mechanisms that may lead 
to improved therapeutic agents. The changes that occur in the brain after an 
injury that leads to epilepsy can be broken into three overlapping temporal 
categories: acute, subacute, and chronic. Acute changes are those changes that 
occur in the brain within the first few minutes to days after an injury. The 
subacute changes take place from hours to weeks and the chronic changes 
taking place over weeks to months after a seizure. These timeframes are 
extremely variable and are used as a simplification to introduce the time course 
of epileptogenesis. The acute changes that occur after an epileptogenic injury 
are activation of immediate early genes, post-translational protein modifications, 
and changes to ion channel activity. The subacute changes in the brain include 
neuronal death, activation of neurotrophic factors, inflammation, neurogenesis 
and alterations in transcription factors. The chronic changes include mossy fiber 
sprouting, dendritic plasticity, and increased susceptibility to recurrent seizures 
(Rakhade & Jensen, 2009).  
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Acute 
Immediate Early Genes 
Immediate early genes (IEGs) are rapidly transcribed in response to 
cellular stimuli, such as neuronal activity, and are implicated in synaptic plasticity 
and synaptogenesis. Many IEGs are transcription factors and DNA-binding 
proteins that have the ability to activate specialized signaling cascades. 
Repeated synaptic activity leads to membrane depolarization with subsequent 
influx of calcium into cells through L-type voltage sensitive calcium channels 
leading to membrane depolarization and opening of NMDA receptor channels 
which in turn induces IEG activation (Murphy et al., 1991). The calcium influx 
following NMDA receptor activation can cause activation of kinase cascades that 
result in phosphorylation of specific transcription factors such as cyclic-AMP 
response element binding protein (CREB) and CREB binding protein (CBP) 
(Greer and Greenberg, 2008). CREB is a basic leucine zipper domain (bZIP) 
transcription factor that is activated when phosphorylated at its Ser133 site. The 
phosphorylated CREB (pCREB) then translocates into the nucleus and dimerizes 
and binds to the promoter consensus sequence TGACGTCA, which is known as 
the cyclic adenosine 3′,5′-monophosphate (cAMP) response element (CRE) 
motif. pCREB along with CBP, a chromatin regulator, has the ability to upregulate 
transcription of target genes (Lonze and Ginty, 2002). The upregulated IEGs can 
activate secondary response genes that have the ability to modulate synaptic 
activity (Greer and Greenberg, 2008). IEGs including Fos, Jun, Egr1, Egr4, 
Homer1, Nurr77, Arc, and Creb, have been identified as activated in adult animal 
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models of epilepsy (Herdegen and Leah, 1998), some as early as 30 minutes 
after seizure induction (Honkaniemi and Sharp, 1999). IEG activation has also 
been seen in the developing brain, but to a lesser degree. Fos and Jun activation 
has been seen in hypoxia-induced seizures and lithium pilocarpine SE models 
(Dubé et al., 1998; Jensen et al., 1993). Activation of Fos differs based on age 
and mode of seizure induction. Hypoxia-induced seizures demonstrated Fos 
activation is confined to layer VI of the neocortex and rarely involves the limbic 
structures as seen with chemoconvulsant models (Jensen et al., 1993).  
Ion Channel and Receptor Post-Transcriptional Regulation 
The calcium influx after a seizure has the ability to activate phosphatases 
and kinases that alter ion channel and neurotransmitter receptor function. The 
calcium-calmodulin activated phosphatase, calcineurin, can lead to GABAA 
receptor endocytosis, decreased inhibitory postsynaptic potential frequency and 
reduced network inhibition after early-life hypoxia-induced seizures (Sanchez et 
al., 2005) and adult pilocarpine-induced SE in vivo (Kurz et al., 2001). The same 
observation of calcineurin regulated GABAA receptor-mediated synaptic inhibition 
has also been seen in neuronal culture and whole hippocampal slices (Khalilov et 
al., 2003). Seizure-induced calcineurin activation causes dephosphorylation and 
endocytosis of GABAA receptors (Sanchez et al., 2005; Blair et al., 2004) and 
Kv2.1 channels (Bernard et al., 2004). Pre-treatment with FK506, a calcineurin 
inhibitor, reversed SE-induced dephosphorylation of GABAA receptor β2/3 
subunits. Calcineurin-mediated dephosphorylation and endocytosis of GABAA 
receptors reduce their inhibitory function and may contribute to neuronal 
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excitability in the hippocampus after seizures and epileptogenesis (Wang et al., 
2009). 
Glutamate receptors contain kinase phosphorylation sites that can be 
activated by seizures in the developing brain. Within minutes after a seizure in 
juvenile rats, protein kinase C activity and calcium-calmodulin dependent kinase 
II (CamKII) activity cause an increase in phosphorylation of Ser831 on GluR1 
and Ser880 on GluR2 subunits of the α-Amino-3-hydroxy-5-methyl-4-
isoxazoleproprionic acid (AMPA) receptor. Protein kinase A activity and 
phosphorylation of Ser845 on GluR1 are also observed (Rakhade et al., 2008). 
The phosphorylation of Ser831 on GluR1 is known to increase channel 
conductance and open-channel probability (Banke et al., 2000),which can lead to 
AMPA receptor-mediated potentiation (Rakhade et al., 2008). Increased 
phosphorylation of Ser880 on GluR2 is known to cause endocytosis of GluR2 
subunit and increased Ca2+ permeability (Chung et al., 2000; Perez et al., 2001). 
NMDA receptor function is potentiated by phosphorylation of NR2A and NR2B 
receptor subunits through activation of cellular sarcoma kinases in the hypoxic-
ischemia model of developmental epilepsy (Jiang et al., 2008).  
Subacute 
Neuronal Death 
Adult models of epilepsy have shown progressive loss of CA3 and CA1 
neurons via necrosis and apoptosis in the hippocampus in response to electrical 
and chemoconvulsant stimulation (Henshall and Simon, 2005; Henshall and 
Murphy, 2008). In adult rats subjected to systemic kainic acid-induced SE 
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significant damage is observed in the thalamus, substantia nigra, cerebral cortex, 
olfactory cortices, amygdala and the hippocampal subfields CA1, CA3, and hilus 
(Schwob et al., 1980; Ben-Ari, 1985; Priel et al., 1996; Haas et al., 2001). In adult 
rats subjected to systemic pilocarpine-induced SE significant damage is 
observed in the thalamus, substantia nigra, neocortex, olfactory cortices, 
amygdala, and the hippocampal subfield CA1, CA3, and hilus is observed (Turski 
et al., 1983; Mello and Covolan, 1996). 
Models of early life seizures have failed to demonstrate neuronal loss in 
the amygdala, hippocampus or temporal cortical regions of animals younger than 
two weeks of age (Holopainen, 2008). There is limited neuronal death seen in the 
hippocampal neurons of immature brains in the fluorothyl-induced seizure model 
(Wasterlain et al., 2002), in the febrile seizure model (Toth et al., 1998), and in 
the hypoxia-ischemia model (Williams et al., 2004) following closely with the 
degree of injury. In the lithium pilocarpine model, regional and age-related 
differences in neuronal cell loss have been demonstrated. In P14 and P21 rats 
exposed to lithium pilocarpine-induced seizures, few damaged neurons were 
seen in the CA1 region of the hippocampus, whereas some neuronal damage 
was observed in the hilar and CA3 regions at P14 with extensive damage at P21 
in some but not all animals (Sankar et al., 1998; Raol et al., 2003). The damage 
is thought to be mediated via necrosis, as demonstrated by eosinophilic cell 
infiltration, and apoptosis, as demonstrated by terminal deoxynucleotidyl 
transferase-mediated biotinylated UTP nick end labeling (TUNEL) stain.  A direct 
relationship between age and vulnerability of neurons in the amygdala and 
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dentate gyrus was also observed (Sankar et al., 1998). Interestingly, the degree 
of hippocampal cell loss did not correlate with risk of later development of 
epilepsy (Raol et al., 2003).  
Some variability in neuronal death in chemoconvulsant models has been 
seen with different routes of administration. Intracerebroventricular (i.c.v.) 
delivery of kainic acid causes more severe acute and progressive damage than 
an intraperitoneal (i.p.) route of delivery. Administration of kainic acid in P7 rats 
i.c.v. causes a dose-dependent acute neuronal loss in the CA3 region of the 
hippocampus with apoptosis seen in CA3 and CA1 as demonstrated by electron 
microscopy and TUNEL staining (Humphrey et al., 2002). However, kainic acid 
induced-SE in P9 rats delivered by i.p. did not produce neuronal damage (Rizzi 
et al., 2003).   
There is another population of neurons that is susceptible to neuronal 
loss, the subplate neurons, in the hypoxic-ischemia model of developmental 
epilepsies (McQuillen et al., 2003). The subplate neurons are located in the deep 
gray matter proper of the neocortex and become interstitial neurons of the 
subcortical white matter during the prenatal and neonatal periods and are 
important for normal maturation of cortical networks, such as the visual cortex 
(Rakic, 1977; Kostovic and Rakic, 1980; Kanold et al., 2003). Subplate neurons 
also possess high levels of NMDA and AMPA receptors (Talos et al., 2006) but 
lack oxidative stress defense mechanisms making them especially susceptible to 
hypoxic-ischemic insults (McQuillen et al., 2003). Administration of antioxidants, 
such as erythropoietin, after acute hypoxia increased the latency of seizures, 
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reduced duration of seizures, protected against hippocampal cell loss, and 
decreased apoptosis in P10 rats (Mikati et al., 2007). 
Neurotrophic Factors 
Neurotrophic factors are important mediators of normal synaptogenesis 
and are expressed at higher levels during postnatal development than in the 
adult brain (Greer and Greenberg, 2008). Early life seizures in animal models 
have been shown to increase neurotrophic factor expression (Tandon et al., 
1999).  Chronic intrahippocampal injection of brain-derived neurotrophic factor 
(BDNF) results in spontaneous limbic seizures through tropomyosin kinase B 
(TrkB) signaling in adult animals, suggesting that BDNF is sufficient to produce 
epileptogenesis (Scharfman et al., 2002). Mice with a conditional knockout of 
TrkB in neurons have been shown to be protected from epileptogenesis 
(McNamara et al., 2006). In the adult rat kindling model, BDNF/TrkB activation 
suppresses the surface expression of potassium chloride cotransporter 2 
(KCC2), a neuron-specific chloride potassium symporter that is responsible for 
maintenance of low intracellular chloride concentrations, thereby transforming the 
chloride gradient such that GABAergic activation is no longer leads to 
hyperpolarizing chloride influx but depolarizing through chloride efflux (Rivera et 
al. 2002). However, BDNF has also been demonstrated to play a neuroprotective 
role during seizures in immature brains. During kainic acid-induced seizures in 
P19 rats, BDNF concentrations increase two-fold and administration of antisense 
oligodeoxynucleotides specific to BNDF increased seizure duration and cell loss 
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of CA1 and CA3 pyramidal cells and hilar interneurons independent of seizure 
duration (Tandon et al., 1999). Further discussion of BDNF is presented below. 
Inflammation 
The inflammatory processes that occur after seizures in the adult brain are 
an important contributor to neuronal cell death (Kunz and Oliw, 2001); however, 
the role of inflammatory processes in the developing brain is not well understood. 
SE-induced glial activation and cytokine transcription is age-dependent. At P9, 
there is very little increase in activation of glia and cytokine induction after kainic 
acid-induced seizures. At P15, immunostaining of microglia and astrocytes 
increased, as did IL-1β mRNA expression and CA3 neuronal injury. At P21, the 
immunostaining of microglia and astrocytes was significantly increased, as was 
IL-1β, TNF-α, IL-6, and Ra (endogenous IL-1 receptor antagonist) and neuronal 
injury in CA1 and CA3 (Rizzi et al., 2003). While the precise mechanism of 
neuronal death is poorly understood; increased cytokine expression may play a 
role. One possible mechanism may be through IL-1β, since IL-1β is known to 
initiate phosphorylation of NMDA receptors (Viviani et al., 2003) thereby altering 
the receptor channel-gating properties to favor Ca2+ influx (Ali and Salter, 2001).  
In the rodent model of prolonged febrile seizure, hippocampal levels of IL-1β 
were significantly higher for over 24 hours after prolonged febrile seizures. 
Chronically, IL-1β levels were elevated only in the subset of rats developing 
spontaneous limbic seizures after febrile SE, consistent with a role for this 
inflammatory mediator in epileptogenesis. (Dubé et al., 2010). 
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Microglia are a glial cell type that reside in the brain and spinal cord and 
function similar to macrophages as active immune defense for the central 
nervous system (CNS). Microglia reach maximal density in the brain during early 
development in the human (Billiards et al., 2006) and rodent (Dalmau et al., 
2003). In addition to the phagocytic role of microglia they are also able to 
produce neurotrophic molecules, cytokines, and chemokines (Kim & de Vellis 
2005). Microglia are also involved in classical complement cascade-mediated 
CNS synapse elimination in the developing brain (Stevens et al., 2007). Seizures 
can directly activate microglia that trigger a cytokine-mediated inflammatory 
response, complement factors and major histocompatibility class factors 
(Vezzani et al., 2008). In adult rats, administration of microglial inactivators, 
minocyclin and doxycycline, have been shown to protect against neuronal death 
in the kainic acid-induced SE model (Heo et al., 2006). This observation was not 
able to be reproduced in juvenile rat kainic acid-induced seizures due to the lack 
of neuronal cell loss in the second postnatal week in this model (Holopainen, 
2008).  
Cytokine activation regulates two main inflammatory pathways: inducible 
nitric oxide synthesis (iNOS) (Romero et al., 1996) and/or cyclooxygenase (COX) 
pathway (Tocco et al., 1997). COX-2 is the rate-limiting enzyme for conversion of 
arachidonic acid to prostaglandins. The enzyme is upregulated in response to 
seizures and may contribute to SE-induced CA3 hippocampal neuron damage in 
adult rats (Tu and Bazan, 2003; Kawaguchi et al., 2005). The expression of 
COX-2 markedly increases between P7 to P14 and reaches adult levels at P21 
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(Tocco et al., 1997). The developmentally-regulated nature of COX-2 expression 
may in part explain the age-dependent effect of inflammation on neuronal death. 
In P9 rats, iNOS and COX-2 were upregulated after NMDA injection-induced 
excitotoxic shock. iNOS was observed in infiltrated neutrophils and in ramified 
protoplasmic astrocytes closely associated with blood vessels whereas COX-2 
was observed in active microglial and neuronal cells (Acarin et al., 2002). In P21 
kainic acid-induced rats, two phases were seen after seizure induction. The first 
phase occurs within 30 minutes, is localized to the hippocampus, and is thought 
to result from kainic acid receptor activation since administration of kainic acid 
receptor antagonists was able to block the effect.  Pre-treatment with a selective 
COX-2 inhibitor, NS398, is able to almost completely inhibit the inflammatory 
process. The late phase of the inflammatory process seems to be due to 
prolonged COX-2 expression localized to the hippocampus (Yoshikawa et al., 
2006). Interestingly, inflammatory mediators can affect neuronal function by 
altering activity-dependent long-term synaptic plasticity, neuronal excitability, and 
synaptic transmission in CA1 pyramidal neurons (Chen & Bazan, 2005).  
Alteration in Transcription of Receptors 
In addition to acute changes in post-translational regulation of ion 
channels and neurotransmitter receptors, seizures can induce transcriptional 
changes in GABA and glutamate receptors (Holopainen, 2008). Kainic acid-
induced seizures in P9 rats are sufficient to alter the normal maturation of GABAA 
receptor expression by altering region-selective expression of α1, α2 β3, and γ2 
subunit mRNAs in the hippocampus that can last up to a week (Laurén et al., 
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2005). In addition to acute and sub-acute changes in GABAA receptor 
composition in young rats, long-term alterations in GABAA receptor α1 subunit 
mRNA and protein expression persisted up to three months in the dentate gyrus 
of the hippocampus in pilocarpine SE-induced P10 and P20 rats (Zhang et al., 
2004; Raol et al., 2006). The shifting role of GABAA receptors from excitatory to 
inhibitory due to age-dependent maintenance of the chloride gradient in the 
developing brain is demonstrated when seizures generated by functional 
excitatory GABAergic synapses cause fast oscillations that are necessary to 
transform normal network activity to an epileptic network (Khazipov et al., 2004). 
Interestingly, in the immature brain, inhibition of GABAA receptors can prevent 
long-lasting sequelae of seizures, whereas in the adult brain GABAA receptor 
inhibition leads to high-frequency seizures (Khalilov et al., 2005). In rats older 
than P30 GABAA receptor α1 subunit mRNA decreases whereas GABAA receptor 
α4 subunit mRNA increases after pilocarpine-induced SE (Brooks-Kayal et al., 
1998). Activation of a specific signaling cascade involving BDNF, Janus kinase 
(JAK)/ signal transducer and activator of transcription (STAT), and CREB are 
linked to the SE-induced alterations in GABAA receptor α1 subunit transcription 
(Lund et al., 2008). 
Seizures also affect the expression of both ionotropic and metabotropic 
glutamate receptor subunits. Down-regulation of kainate receptors in the CA3 
and dentate gyrus was observed in recurrent kainic acid-induced seizures in P12 
rats (Tandon et al. 2002). In addition, elevation of mGluR1α protein expression 
was seen in the inhibitory interneurons of the CA1 stratum oriens-alveus of the 
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same kainic acid-induced model persisting through adulthood. This change in 
mGluR1α expression may induce synchrony of the limbic network, suppression of 
which could prevent further seizure propagation (Avallone et al., 2006). There is 
a decrease in GluR2 protein levels at P10 after lithium-pilocarpine (Zhang et al., 
2004) and hypoxia-induced seizures (Sanchez et al. 2001). The decrease in 
GluR2 levels could be explained by excitotoxicity that activates the repressor 
element 1-silencing transcription factor (REST), a regulator of gene transcription 
that can affect circuit excitability, which thereby suppresses mGluR2 promoter 
activity leading to AMPA receptor-mediated neuronal death (Calderone et al., 
2003). Ionotropic glutamate receptors such as NMDA receptors are responsible 
for excitotoxicity seen with prolonged receptor activation and Ca2+ influx in 
seizure-related neuronal death in adult rats (Furukawa et al., 1997).   
Pilocarpine-induced SE in P14 rats showed increased AMPA GluR2 and 
kainate KA2 subunit mRNAs with decreases in AMPA GluR3 and kainate GluR6 
mRNAs, but only in mature dentate granule cell neurons. In the study, immature 
dentate granule cells only showed a decrease in kainate GluR6 mRNA levels 
(Porter et al., 2006). These changes to kainate receptor subunits may play a role 
in altered kainate receptor conductance and dentate granule cell excitability seen 
in chronic epilepsy (Epsztein et al., 2005). At P7, a single kainic acid-induced 
seizure has the ability to cause a long-term increase in intracellular GluR1 and 
decrease NR2A subunits and an increase in PSD-95 expression, a primary 
subsynaptic scaffold, in CA1 (Cornejo et al., 2007).  
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Neurogenesis 
Increased neurogenesis has been seen in autopsy specimens and tissue 
biopsies from pediatric epilepsy surgery patients (Takei et al., 2007). Timing of 
the seizure insult plays a very important role in seizure-induced neurogenesis. 
When seizures are induced at one to four weeks of age long-term increases in 
dentate granule cell number after lithium pilocarpine-induced SE (Sankar et al., 
2000; Porter et al., 2004) are observed.  Lithium pilocarpine-induced SE rats at 
P20 showed a six-fold increase in BrdU labeling eight days after SE induction in 
the dentate gyrus that went down to a three-fold increase three weeks after 
induction. In addition to increased neurogenesis, an increase in apoptosis was 
observed in the same samples as determined by a three-fold increase TUNEL 
staining eight days after induction as compared to controls. Only a subset of the 
newborn cells actually went on to become mature neurons as demonstrated by 
NeuN staining (Porter et al., 2004). The number of episodes of SE and type of 
chemoconvulsant also has important implications for neurogenesis. One or two 
episodes of kainic acid-induced seizures showed no difference at P6 and P9 in 
BrdU labeling in the dentate gyrus when compared to controls. However, three 
episodes of kainic acid-induced seizures demonstrated a decrease in BrdU 
labeling in the dentate gyrus at P6, P9, and P13 at 48 hours after seizure. No 
difference in cell death or apoptosis was observed in the kainic acid-induced SE 
rats when compared to controls; however, the newly-born cells demonstrate 
irregular morphology (Liu, 2003). Alterations in neurogenesis may have a 
significant functional impact on normal brain development. Only about 20 percent 
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of granule cells have developed at P0 and only about half of all granule cells are 
present at P5 in normal rat brain development (Bayer, 1980), therefore the age at 
the onset of injury may be an important factor that influences neurogenesis.  
Chronic 
Sprouting 
In adult rodent models of epilepsy and chronic epileptic foci removed from 
adult and older pediatric patients, hippocampal granule cell mossy fibers “sprout” 
aberrant collaterals to the inner molecular layer of the dentate gyrus forming 
monosynaptic connections and a positive feedback loop that may contribute to 
the seizure focus (Williams et al., 2007). In the adult sprouting is localized to the 
supragranular region that is a result of cell loss in the hilus and CA3 (Liu et al., 
1999). In P20 rats subjected to lithium pilocarpine-induced SE that developed 
spontaneous seizures approximately 33 percent exhibit observable mossy fiber 
sprouting (Raol et al., 2003). There is some controversy regarding the effect of 
sprouting on epileptogenesis. Early studies have demonstrated that direct 
infusion of the protein inhibitor, cyclohexamide, was able to block pilocarpine- 
and kainic acid-induced mossy fiber sprouting in adult rats but not 
epileptogenesis (Longo and Mello, 1997). However, more recently studies 
demonstrated direct infusion of cyclohexamide to the dentate gyrus of adult rats 
spanning the period of pilocarpine treatment was unable to block mossy fiber 
sprouting or epileptogenesis (Williams et al., 2002; Toyoda and Buckmaster, 
2005).  
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The role of mossy fiber sprouting is still unclear. Some hypothesize that the 
sprouting is caused by hyperexcitability, however recent studies have not 
supported this hypothesis. In adults, blocking L-type calcium channels and 
sodium channels is unable to stop mossy fiber sprouting in the pilocarpine model 
(Buckmaster, 2004; Ingram et al., 2009). However, in P14 mice pilocarpine-
induced L-type calcium channel blockade was able to inhibit mossy fiber 
sprouting (Ikegaya et al., 2000). Early treatment with rapamycin, an inhibitor of 
the mammalian target of rapamycin (mTOR), was able to decrease seizure 
susceptibility in a transgenic mouse model of tuberous sclerosis (Meikle et al., 
2008) and block mossy fiber sprouting in the pilocarpine model with constant 
infusion, with sprouting developing after the infusion ceased (Buckmaster et al., 
2009). It was thought that mossy fiber sprouting yielded recurrent circuits that led 
to hyperexcitability. However, recently this closely held dogma has been 
disproven by utilizing administration of rapamycin, an inhibitor of the mTOR 
pathway, which prevent mossy fiber sprouting and had no effect on frequency of 
spontaneous seizures in pilocarpine-induced SE mice (Buckmaster and Lew, 
2011; Heng et al., 2013). Administration of rapamycin was able to prevent 
excitatory synapses from synapsing with proximal dendrites of granule cells 
(Yamawaki et al., 2015) calling in to question the recurrent excitation hypothesis 
of temporal lobe epilepsy.  
Bioenergetics 
Metabolic dysfunction may play an important role in human TLE since 
glycolytic rates, activity-matched cerebral blood flow, and lactate/pyruvate ratios 
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are acutely increased during seizure activity (Kawai et al., 2006). This period of 
hypermetabolism is followed by an interictal period of hypometabolism during 
which the mitochondrial bioenergetics capacity may be depleted (Spencer, 
1994). Levels of reactive oxygen species (ROS), a byproduct of metabolism, are 
increased after chemoconvulsant and kindling models of epilepsy in rats and 
mice (Frantseva et al., 2000; Gluck et al., 2000; Liang et al., 2000; Peterson et 
al., 2002; Sashindranath et al., 2010). The redox status in the brain is altered 
after experimental models of TLE as demonstrated by a decrease in the 
glutathione/glutathione disulfide ratio, coenzyme A thiol/coenzyme A disulfide 
with GSH ratio, and depletion of glutathione in the first 7 days following 
administration of kainic acid in rats, providing evidence for seizure-induced 
mitochondrial oxidative stress and altered redox status (Liang and Patel, 2006). 
Acutely after SE and in the chronic phase of epileptogenesis levels of 
mitochondrial superoxide and hydrogen peroxide are increased in rats by 
inactivation of superoxide-sensitive aconitase, a member of the tricarboxylic acid 
cycle and a measure of mitochondrial oxidative stress (Jarrett et al., 2008).  
These findings provide evidence for direct involvement of mitochondrial 
oxidative stress in oxidative DNA damage at different phases of kainic acid- and 
lithium pilocarpine-induced epileptogenesis in rats demonstrating some level of 
model independence of these findings (Jarrett et al., 2008; Waldbaum et al., 
2010). ROS are produced by inhibition of the respiratory chain in mitochondria 
which can overload endogenous protective mechanisms (glutathione peroxidase, 
superoxide dismutase, and catalase) resulting in oxidative damage to proteins, 
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phospholipids, and mitochondrial DNA. This inhibition of the mitochondrial 
respiratory chain is observed in vulnerable CA1 and CA3 hippocampal subfields 
without involvement of the resistant dentate gyrus in rats (Kudin et al., 2002, 
2004, 2005; Malinska et al., 2010). Most recently mitochondrial bioenergetics 
dysfunction was observed in the acute and chronic phases of epileptogenesis in 
rats as determined by direct measurement of mitochondrial function in isolated 
hippocampal synaptosomes from kainic acid treated rats. The mitochondrial 
dysfunction observed in kainic acid treated rats is at least in part due to 
production of ROS since scavenging ROS acutely after kainic acid administration 
is able to partially attenuate mitochondrial respiration deficits (Rowley et al., 
2015).   
Gliosis 
Glia play an important role in a diverse array of neuronal functions 
including guiding migration of developing neurons, ensheathing axons, regulating 
the extracellular microenvironment by buffering ion, water, and neurotransmitter 
concentrations, regulating local blood flow and blood-brain barrier permeability. A 
single rodent astrocyte domain can cover 20,000-120,000 synapses (Bushong et 
al., 2002; Oberheim et al., 2009). The modulatory effects of glia on synaptic 
transmission have led to the emergence of the concept of the tripartite synapse 
(Araque et al., 1999; Halassa et al., 2007). Glia also play an important role in the 
pathophysiology of epileptogenesis; however, since the breadth of the role of glia 
in epilepsy is quite vast only a limited discussion will be presented. After SE 
reactive astrocytes become hypertrophic and are observed in pilocarpine and 
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kainic acid models of SE in both rats and mice (Nadler et al., 1980; Nitecka et al., 
1984; Niquet et al., 1994; Borges et al., 2003). The processes of the reactive 
astrocytes become hypertrophied with an increase in expression of glial fibrillary 
acidic protein (GFAP). In a pilocarpine-induced SE models of TLE in C57BL/6J 
mice, reactive astrocytes are observed in the hippocampus at 10 days and up to 
31 days after SE (Borges et al., 2003). A distinct loss in astrocytic domain 
organization in the CA3 region of the hippocampus is observed in kainic acid-
induced SE mice up to 6 months after SE (Oberheim et al., 2008).  
 An important function of astrocytes in the brain is regulation of 
extracellular microenvironment. One of the modes of regulating the extracellular 
microenvironment is through regulating fluid osmolarity and extracellular space 
(ECS) volume. Aquaporin-4 (AQP-4) is the main water channel in the brain and is 
predominately localized in the astrocyte perivascular endfeet and perisynaptic 
processes (Nielsen et al., 1997). A reduction in ECS volume is able to produce 
hyperexcitability and increased epileptiform activity (Dudek et al., 1990; Roper et 
al., 1992). Increasing ECS volume had an opposite effect and was able to 
attenuate hyperexcitability in hippocampal slices exposed to supraphysiological 
levels of extracellular potassium or calcium-free bathing medium (Traynelis and 
Dingledine, 1989; Dudek et al., 1990). During normal synaptic activity much of 
the potassium released in the ECS by neuronal firing is taken up by astrocytes 
and neurons. The potassium uptake is normally accompanied by water influx via 
AQP4 into astrocytes in the perisynaptic space and excess water is dumped via 
AQP4 at the perivascular endfeet. However, during seizures focal swelling in the 
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area of the seizure focus is observed thought to be caused by AQP4 
redistribution (Traynelis and Dingledine, 1989; Eid et al., 2005; Binder et al., 
2006; Lee et al., 2012; Alvestad et al., 2013). A reduction in AQP4 protein 
expression and its anchoring partner in perivascular endfeet is observed in 
patients with TLE (Eid et al., 2005). In the kainic acid-induced SE model in rats 
dislocalization of AQP4 precedes the chronic phase of epilepsy suggesting that 
astrocytic dysfunction may be of pathophysiological relevance (Alvestad et al., 
2013). A similar dislocalization of AQP4 expression was observed in the 
intrahippocampal kainic acid model of SE in mice (Lee et al., 2012).  
Neurotrophins 
Introduction 
The field of neurotrophin research was initiated by the discovery of a 
diffusible factor from mouse sarcoma cells that promoted the growth of nerve 
cells in chick embryos (Levi-Montalcini and Hamburger, 1953). Subsequent 
studies observed the same effect with protein purified from cobra venom and 
mouse salivary glands (Cohen and Levi-Montalcini, 1956; Cohen, 1960). 
Isolation of the “diffusible growth promoting protein” paved the way for structural, 
biochemical and functional characterization of what was dubbed nerve growth 
factor (NGF), the first member of the neurotrophin family to be discovered. Over 
20 years later, the second member of the neurotrophin family was discovered, 
Brain Derived Neurotrophic Factor (BDNF), which was isolated from pig brain 
homogenates by Yves-Alain Barde and colleagues in 1982 and was shown to 
exhibit a trophic effect on placode-derived sensory neurons (Barde et al., 1982). 
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BDNF promotes growth and differentiation of neurons during development and 
plays an important role in physiological processes, such as learning and memory, 
as well as pathological processes, such as epileptogenesis (Lu et al., 2014). 
BDNF synthesis and expression is highly regulated throughout the nervous 
system (reviewed in Leßmann and Brigadski, 2009).  
Brain-Derived Neurotrophic Factor 
Since most studies on BDNF were done in mouse models, the discussion 
regarding BDNF transcription, translation, processing, and trafficking will be 
restricted to those findings observed in rodents. The BDNF gene is under 
complex transcriptional regulation. It can be transcribed from at least eight 
different promoters with two possible polyadenylation sites leading to mRNA 
transcripts with a short 3’ untranslated region (UTR) or a long 3’UTR (Aid et al., 
2007). At least 18 different transcripts can be produced through alternative 
promoters, splicing, and polyadenylation sites; however, each encodes identical 
initial BDNF protein products (figure 1.1A, Greenberg et al., 2009). The short 
3’UTR is restricted to the soma; however, the long 3’UTR is targeted to the 
dendrites for local translation (An et al., 2008). Somatic short 3’UTR Bdnf 
transcripts are important for spine formation, whereas dendritically targeted long 
3’UTR Bdnf mRNA transcripts are important for spine maturation and pruning 
(Orefice et al., 2013).  
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Figure 1.1: Bdnf gene structure and transcripts, processing, and protein 
structure. 
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Figure 1.1: Bdnf gene structure and transcripts, processing, and protein 
structure. A) Mouse Bdnf gene structure and transcripts. Exons are indicated by 
boxes. Filled box in exon IXA indicates the coding region of the Bdnf gene. Lines 
indicate splice variants. Arrows indicate within-exon splice sites and alternative 
polyadenylation sites. The Bdnf gene is transcribed from different promoters, 
immediately preceding each of the 5′ exons (exons I–VIII), so that each full-
length transcript contains a unique 5′-exon and a common 3′-exon (exon IXA) 
that encodes the BDNF protein. Transcript BDNF6B results from splicing events 
that incorporate exons VII, VIII and IXA. (Cunha et al., 2010) B) 2.3 Å-resolution 
X-ray diffraction crystal structure of human BDNF (top) complexed with NT-3 
(bottom). PDB ID:1bnd. (Robinson et al., 1995) C) A schematic showing the 
synthesis and sorting of brain-derived neurotrophic factor (BDNF) in a typical 
neuron. First synthesized in the endoplasmic reticulum (ER) (1), proBDNF 
(precursor of BDNF) binds to intracellular sortilin in the Golgi to facilitate proper 
folding of the mature domain (2). A motif in the mature domain of BDNF binds to 
carboxypeptidase E (CPE), an interaction that sorts BDNF into large dense core 
vesicles, which are a component of the regulated secretory pathway. In the 
absence of this motif, BDNF is sorted into the constitutive pathway. After the 
binary decision of sorting, BDNF is transported to the appropriate site of release, 
either in dendrites or in axons. Because, in some cases, the pro-domain is not 
cleaved intracellularly by furin or protein convertases (such as protein convertase 
1, PC1) (3), proBDNF can be released by neurons. Extracellular proteases, such 
as metalloproteinases and plasmin, can subsequently cleave the pro-region to 
yield mature BDNF (mBDNF) (4). MMP, matrix metalloproteinase. (Lu et al., 
2005) 
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Mouse Bdnf mRNA is translated as a 249-amino acid peptide referred to 
as preproBDNF, which contains four main elements: an eighteen amino acid 
signal peptide important for proper intracellular sorting of the protein, a 112-
amino acid pro-domain that contains sites for glycosylation and pairs of basic 
amino acids that are recognized by processing enzymes leading to cleavage, 
and a 119-amino acid mature BDNF (mBDNF) sequence. The structure of 
mBDNF is described as a distinct cysteine knot structure that contains two pairs 
of anti-parallel β-strands and cysteine residues (figure 1.1B, Robinson et al., 
1995).  
ProBDNF is produced as a 32kDa precursor that undergoes N-
glycosylation and glycosulfation in the secretory pathway at a single putative 
consensus sequence for N-linked glycosylation (Asn-X-Thr/Ser) six residues 
upstream from the mature BDNF cleavage site (Mowla et al., 2001). Mature 
BDNF can be produced intracellularly by furin-mediated cleavage in the trans-
Golgi or by proprotein convertase in immature secretory granules (Mowla et al., 
1999). Recent studies have shown that the cleaved prodomain is stored and co-
secreted with mBDNF via dense core vesicles (DCVs) (Dieni et al., 2012). 
ProBDNF can also be cleaved extracellularly by matrix metalloproteinases 
(MMP) -3, -7, or -9, or by components of the tissue plasminogen 
activator/plasmin (tPA/plasmin) proteolytic cascade (figure 1.1C, Lee et al., 2001; 
Pang et al., 2004). ProBDNF cleavage produces the 120-amino acid mBDNF 
which exists as noncovalently-associated dimers of approximately 13.5kDa 
protomers (figure 1.1B, Rosenthal et al., 1991).  
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BDNF is present in both pre- and postsynaptic compartments and can 
undergo both retrograde and anterograde transport. BDNF selectively traffics 
through the activity-dependent regulated secretory pathway (Griesbeck et al., 
1999; Mowla et al., 1999). Release of BDNF can occur through three 
mechanisms dependent on the site of release: 1) calcium influx-dependent 
release from presynaptic sites mediated by calcium influx through ionotropic 
glutamate receptors and voltage gated calcium channels (Hartmann et al., 2001), 
2)  calcium influx-dependent release from presynaptic sites that relies on calcium 
release from intracellular stores (Balkowiec and Katz, 2002), and 3) calcium 
influx-independent release that relies on calcium release from intracellular stores 
(Griesbeck et al., 1999).  
Neurotrophin Receptors 
Mature BDNF is able to bind and activate pre- and postsynaptically two 
different transmembrane protein receptors, the TrkB receptor with high affinity (Kd 
= 1.7 x 10-11M) and the pan neurotrophin receptor p75NTR with low affinity (Kd = 
1.3 x 10-9M) a difference in affinity by ~100 fold (Rodriguez-Tébar and Barde, 
1988). ProBDNF binds p75NTR preferentially with high affinity (Teng et al., 2005). 
MBDNF binds TrkB preferentially with high affinity. (Rodriguez-Tébar and Barde, 
1988) 
Tropomyosin-related Kinase B 
 TrkB is a receptor tyrosine kinase and can activate three major signaling 
pathways: phospholipase Cγ (PLCγ), phosphotidylinositol 3-kinase (PI3K), and 
the extracellular signal-regulated kinases (ERK), which is a member of the 
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mitogen-activated protein kinase (MAPK) family (figure 1.2, reviewed in Segal, 
2003; Skaper, 2008). BDNF binding to TrkB receptor results in dimerization and 
autophosphorylation of specific tyrosine residues in the cytoplasmic domain of 
TrkB. Transphosphorylation of Tyr816 (Y816), the most C-terminal tyrosine, 
leads to recruitment and activation of PLCγ which leads to subsequent release of 
intracellular calcium stores and activation of CaMKII, CaMKIV, and the 
phosphatase calcineurin (Shieh and Ghosh, 1999). This elevation in intracellular 
calcium plays an important role in expression of activity-induced gene products 
such as BDNF. CaMKII activation can become sustained and independent of 
calcium and CaM through calcium- and CaM-dependent autophosphorylation of 
Thr286 on CaMKII (Miller and Kennedy, 1986). CaMKIV is able to phosphorylate 
the transcription factor CREB (Deisseroth et al., 1998). Furthermore, CaMKII 
phosphorylates methyl-CpG-binding protein 2 (MeCP2) (Zhou et al., 2006), 
leading to dissociation of MeCP2, (Tian et al., 2010) which allows 
phosphorylation of CREB and other transcription factors such as calcium 
response factors (CaRF) that promote Bdnf gene transcription (Tao et al., 2002; 
Chen et al., 2003; Martinowich et al., 2003). After protein synthesis activity-
dependent release of stored BDNF requires calcium-dependent activation of 
CaMKII and ryanodine receptor mediated calcium release (Balkowiec and Katz, 
2002; Kolarow et al., 2007).  
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Figure 1.2: Major TrkB-signalling-activated pathways. 
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Figure 1.2: Major TrkB-signalling-activated pathways. The interaction 
between the receptor tyrosine kinase TrkB and neurotrophins activates three 
main intracellular signaling pathways. Phosphorylation and recruitment of 
adaptors to Y515 (Tyr515) leads to activation of the Ras–mitogen-activated 
protein kinase (MAPK) signaling cascade, which promotes neuronal 
differentiation and growth through MAPK/ERK kinase (MEK) and extracellular 
signal-regulated kinase (ERK), and to activation of the phosphatidylinositol 3-
kinase (PI3K) cascade, which promotes survival and growth of neurons and other 
cells through Ras or GRB-associated binder 1 (GAB1). Recruitment and 
activation of phospholipase Cγ1 (PLCγ1) through phosphorylation of Y816 
(Tyr816) results in the generation of inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) 
and diacylglycerol (DAG). Whereas DAG stimulates protein kinase C (PKC) 
isoforms, Ins(1,4,5)P3 promotes the release of Ca2+ from internal stores and 
subsequent activation of Ca2+/calmodulin (Ca2+/CaM)-dependent protein 
kinases (CaMKII, CaMKK and CaMKIV). Point mutation of Y816F impairs 
phosphorylation of CaMKII, CaMKIV and cyclic AMP-responsive element-binding 
protein (CREB) and synaptic plasticity. Pathways activated through the Shc 
adaptor protein site (Ras–MAPK and PI3K) are not impaired by Y816F mutation. 
Each of these signaling pathways also regulates gene transcription and some 
may be involved in long-term potentiation (LTP). PLCγ1 is also able to associate 
with GAB1, which may stabilize the formation of the complex that forms 
downstream of TrkB on activation. Some additional adaptors, such as the Src 
homology domain-containing protein SH2B and SH2B2, have been identified that 
interact with TrkB. Abbreviations: BDNF, brain-derived neurotrophic factor; 
FRS2, fibroblast growth factor receptor substrate 2; GRB2, growth factor 
receptor-bound protein 2; PDPK1, 3-phosphoinositide-dependent protein kinase 
1; PtdIns(4,5)P2, phosphatidylinositol-4,5-bisphosphate; RSK, ribosomal protein 
S6 kinase; SHP2, SRC-homology phosphatase 2; SOS, son of sevenless 
(Adapted from Minichiello, 2009). 
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Secreted BDNF binds to TrkB which undergoes autophosphorylation 
(McCarty and Feinstein, 1998), which leads to presynaptic release of glutamate 
thereby increasing the expression, activation of pre- and postsynaptic sites, and 
clustering at postsynaptic sites of NMDA receptors (Elmariah et al., 2004; 
Caldeira et al., 2007; Madara and Levine, 2008). Activation of L-type calcium 
channels and NMDA receptors leads to increased calcium influx which mediates 
BDNF-TrkB complex internalization (Du et al., 2003). The BDNF-TrkB complexes 
are able to induce expression of ryanodine receptors through potentiation of 
calcium signaling (Adasme et al., 2011). Persistent synthesis and release of 
BDNF increases TrkB activation and BDNF-TrkB complex formation and 
internalization through NMDA receptor and calcium channels, which leads to 
increased calcium influx and sustained synthesis of BDNF and TrkB. Taken 
together, BDNF is able to regulate its own expression via activation of calcium-
dependent signaling. 
BDNF binding to TrkB also leads to transphosphorylation of Y515 allowing 
association of src homology-type 2 (SH2) linker proteins such as src homology 
domain containing (Shc) and insulin receptor substrate-1 and -2 (IRS1, IRS2). 
This association leads to activation of ERK and PI3K signaling pathways.  Src 
recruits adaptor proteins, growth factor receptor-bound protein 2 (Grb2) and/or 
son of sevenless (SOS), initiating guanosine-5'-triphosphate (GTP) loading and 
the activation of the Ras/Raf/MEK/ERK kinase cascade (Nimnual et al., 1998). 
Phosphorylated ERK translocates to the nucleus and activates transcription 
factors such as CREB to regulate gene expression. On the other hand, Grb2 can 
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also associate with Grb2-associated binding protein 1, Gab1, to activate PI3K 
and the downstream protein kinase B (Akt). BDNF also has the ability to activate 
PI3K through direct interaction with IRS1/IRS2 and PI3K (Yamada et al., 1997). 
Activation of the PI3K signaling has been shown to mediate the neuroprotective 
effects of BDNF in hippocampal neurons (Zheng and Quirion, 2004). BDNF is 
also able to facilitate local translation of proteins in dendrites by activation of 
mTOR through PI3K activation (Schratt et al., 2004). BDNF has been shown to 
play an important role in long-term potentiation (LTP), glutamatergic 
neurotransmission, and GABAergic neurotransmission through activation of the 
above pathways (reviewed in Cunha et al., 2010). 
BDNF can also bind TrkB receptor splice variants that lack the tyrosine 
kinase domain necessary for downstream signaling, known as truncated TrkB 
receptors (TrkB.T1 or TrkB.T2) (Klein et al., 1990). TrkB.T1 is located primarily in 
hippocampal astrocytes whereas TrkB.T2 is primarily located in hippocampal 
neurons (Silhol et al., 2005). These truncated receptors can function as a 
dominant-negative inhibitor by forming heterodimers with full-length TrkB leading 
to internalization of BDNF and triggering clearance of BDNF and TrkB 
(Haapasalo et al., 2002). Activation of TrkB.T1 has been linked to signal 
transduction and activation of calcium signaling in astrocytes (Rose et al., 2003). 
Low Affinity Neurotrophin Receptor – p75NTR 
 The pan neurotrophin receptor p75NTR was discovered independently by 
two groups after the earlier observation in cross-linking studies with NGF in 
sensory neurons (Massague et al., 1981) and in PC12 cells (Massague et al., 
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1982; Grob et al., 1983) revealed a 70-100kDa binding partner that was 
subsequently cloned and named the p75 receptor (Chao et al., 1986; Radeke et 
al., 1987). Initially it was thought that the p75NTR served as a binding partner of 
TrkA to increase local concentration of NGF to facilitate activation of tropomyosin 
receptor kinase A (TrkA) (Chao and Hempstead, 1995). P75NTR is expressed by 
many neuronal cell types in addition to neural stem cells, some astrocytes, 
oligodendrocyte precursor cells, Schwann cells, and olfactory ensheathing glia 
(Cragnolini and Friedman, 2008). P75NTR binds with neurotrophins through four 
40-amino acid cysteine-rich domains in its extracellular domain forming a 2:2 
complex (Baldwin and Shooter, 1995; Gong et al., 2008; Feng et al., 2010). The 
intracellular domain (ICD) consists of 80 amino acids and mediates p75NTR 
apoptotic signaling, bears much resemblance to the tumor necrosis factor (TNF) 
receptor and the Fas antigen, and is often referred to as the “death domain” 
(Chapman, 1995; Chapman and Kuntz, 1995).  
Activation of p75NTR is able to induce apoptosis in a wide variety of 
neuronal and non-neuronal cell types, including hippocampal neurons (Volosin et 
al., 2008; Le and Friedman, 2012). Activation of p75NTR by neurotrophin binding 
mediates apoptosis through activation of c-Jun N-terminal kinase (JNK) via 
interactions with TNF receptor-associated factor 6 (TRAF6), neurotrophin 
receptor-interacting factor (NRIF), and neurotrophin receptor-interacting MAGE 
homolog (NRAGE). In addition to the above mentioned pathway, p75NTR can 
associate with several other proteins to regulate apoptosis (figure 1.3, reviewed 
in Skeldal et al., 2011; Almeida and Duarte, 2014). P75NTR is also able to 
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undergo regulated intramembrane proteolysis to facilitate apoptosis. The 
extracellular domain (ECD) is first cleaved by metalloproteinase TNFα-converting 
enzyme (TACE, also known as ADAM17) producing a 24kDa membrane-bound 
C-terminal fragment (p75NTR-CTF) (Weskamp et al., 2004).  
 
Figure 1.3: p75NTR proteolysis and cell death signaling pathways. Regulated 
intracellular proteolysis of p75NTR leading to neuronal cell death can act through 
two distinct pathways. (a) In one model, the 29 amino acid intracellular 
juxtamembrane region of p75NTR named “chopper” induces cell death through 
activation of G-protein-coupled inwardly rectifying potassium (GIRK/Kir3) 
channels. The corresponding potassium efflux supposedly leads to apoptosome 
activation and by consequence neuronal cell death. (b) In another model p75NTR 
activates JNK 3 (1), which leads to the transcription-dependent upregulation of α-
secretase (2) that cleaves p75NTR extracellular domain (3). γ-secretase releases 
the ICD into the cytoplasm (4) which associates with the DNA-binding protein 
neurotrophin receptor interacting factor (NRIF) and the E3 ubiquitin ligase TRAF6 
(5). The formation of this ternary complex leads to TRAF6-dependent 
ubiquitination of NRIF (6) and nuclear translocation (7), a process required for 
p75NTR-dependent cell death (8). In parallel, this ternary complex further activates 
JNK3 (9), amplifying the apoptotic signal (10). (Adapted from Almeida and 
Duarte, 2014). 
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The transmembrane domain of p75NTR-CTF is further cleaved by γ-secretase 
releasing the 19kDa intracellular domain (p75NTR-ICD). In a model of pilocarpine-
induced seizures, cleavage of p75NTR permitted NRIF nuclear translocation 
leading to hippocampal neuronal cell death. The number of apoptotic neurons 
was significantly reduced in p75NTR -/- (Troy et al., 2002) and in nrif -/- mice 
(Volosin et al., 2008). 
Much of the work on the function of p75NTR has focused on its role in 
apoptosis; however, in certain contexts p75NTR promotes cell survival. P75NTR is 
also able to associate with Trk receptors to enhance cell survival. Co-expression 
of p75NTR with TrkA increases the affinity of TrkA for NGF by 100-fold 
(Hempstead et al., 1991; Esposito et al., 2001). Co-expression of p75NTR with 
TrkB increases the specificity of TrkB receptor for BDNF rather than lower affinity 
ligands such as neurotrophin-3 and neurotrophin-4/5 (Bibel et al., 1999). In 
addition to regulating the affinity and selectivity of Trk receptors, p75NTR is able to 
potentiate the cell survival function of Trks; however, this mechanism is poorly 
understood. Two possible mechanisms for this potentiation of Trk signaling 
through p75NTR include ubiquitination of Trks with delayed internalization and 
degradation (Makkerh et al., 2005) and/or by prolonging cell surface expression 
of the Trk receptor (Kong et al., 2001). Another site of regulation by co-activation 
of p75NTR and Trk receptors is modulation of the pro-survival kinase Akt. 
Treatment of PC12 cell with NGF in the presence of a p75NTR function blocking 
antibody inhibited the activation of Akt (Bui et al., 2002). Recently, it has been 
shown that cleavage of p75NTR induced by Trk activation is necessary for 
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potentiation of neurotrophin-induced survival signaling (Ceni et al., 2010; 
Kommaddi et al., 2011).   
Regulation of Cleavage Enzymes 
The activity of these proteases remains under tight regulation. Plasminogen 
activator inhibitor-1 (PAI-1) inhibits both tPA and furin, thereby inhibiting both 
extracellular and intracellular cleavage (Binder et al., 2002; Dupont et al., 2009; 
Bernot et al., 2011, summarized in figure 1.4). In addition, tissue inhibitor of 
metalloproteinases (TIMPs) inhibit matrix metalloproteinases (MMPs) while 
neuroserpin and α2 antiplasmin (A2AP) inhibit the tPA/plasmin proteolytic 
cascade (Hastings et al., 1997; Krueger et al., 1997; Brew et al., 2000; Yepes 
and Lawrence, 2004; Coughlin, 2005).  
 
Figure 1.4: Schematic representation of different proteins involved in the 
cleavage of BDNF through extracellular and intracellular mechanisms.  
 
The described studies primarily evaluated levels of cleavage enzymes; 
however, cleavage inhibitors are known to play an important role in cleavage 
enzyme activity. Neuroserpin inhibits cleavage at the level of tPA and both have 
been shown to be elevated at 30-60 minutes following intra-amygdala kainic acid 
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induced seizures (Yepes et al., 2002). PAI-1 mRNA is acutely elevated in the 
hippocampus after kainic acid induced seizures in mice for up to three days 
(Masos and Miskin, 1997). Increased levels of PAI-1 mRNA is also observed in 
human TLE patients that exhibit hippocampal sclerosis and focal cortical 
dysplasia (Iyer et al., 2010). Elevation in PAI-1 protein expression was observed 
in the ipsilateral hippocampus at 24 hours after intrahippocampal kainic acid 
induced seizures in mice triggering a decrease in tPA activity (Salles and 
Strickland, 2002). TIMPs, inhibitors of MMPs, are also elevated after seizure. 
TIMP-1 mRNA is elevated in rat dentate gyrus after kainic acid injection (Nedivi 
et al., 1993). Furthermore, elevated TIMP-1 mRNA was observed in neurons and 
glia after kainic acid- and PTZ-induced seizures in rodents under the control of 
activator protein 1 (AP-1) transcription factor (Rivera et al., 1997; Jaworski et al., 
1999). Increases in TIMP-1 immunoreactivity was observed eight hours after 
kainic acid injection in the perisomatic and dendro-axonic areas of the 
hippocampus, suggesting secretion of the inhibitor. At three days after kainic acid 
administration TIMP-1 was observed in astrocytes and dendro-axonic projection 
of resistant neurons (Rivera et al., 1997). TIMP-1 knockout mice subjected to 
kainic acid-induced seizures were resistant to excitotoxicity and had altered 
mossy fiber sprouting when compared to wild-type mice (Jourquin et al., 2005). 
In another study, proNGF levels were elevated after kainic acid-induced seizures. 
This elevation in proNGF was observed in the presence of elevated MMP-7 
expression concomitantly with TIMP-1. A decrease in cleavage activity was 
observed leading to decreased proneurotrophins cleavage with a corresponding 
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increase in levels of proNGF in the extracellular milieu (Le and Friedman, 2012). 
Taken together, these data support the conclusion that proteolytic cleavage may 
be inhibited after seizure.  
Possible Role of Neurotrophins in Epileptogenesis 
As described above there are many changes that occur after a brain injury 
that contribute to development of epilepsy. Normal brain activity can be thought 
of as a homeostatic balance between excitation and inhibition. However, in 
epilepsy there is a breakdown of this homeostatic balance leading to excessive 
synchronized excitation. GABAA receptors are the main inhibitory receptor in the 
adult brain and are an area of intense research in epilepsy models. Previously 
published research from the Brooks-Kayal laboratory has demonstrated that 
following SE in rats there is a BDNF-mediated phosphorylation of STAT3 leading 
to upregulation of the cAMP response element–binding protein (CREB) family 
member inducible cAMP early repressor (ICER), which then binds to and 
represses the promoter of the GABAR α1 subunit gene (Lund et al., 2008). In 
addition, GABAA receptor α4 subunit expression increases through BDNF-
mediated TrkB activation of the protein kinase C (PKC)/mitogen-activated protein 
kinase (MAPK) pathway and early growth response protein 3 (EGR3) 
upregulation in rats after SE (Roberts et al., 2006). Alterations in GABAA receptor 
subunit composition and localization can have significant effects on synaptic 
inhibition through diminished sensitivity to benzodiazepines, enhanced sensitivity 
to zinc blockade, reduced neurosteroid modulation, and diminished phasic 
inhibition in dendrites (Buhl et al., 1996; Gibbs et al., 1997; Cohen et al., 2003; 
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Sperk et al., 2007). α1 and α4 subunit containing GABAARs possess different 
functional characteristics and sensitivities to pharmaceutical agents. Receptors 
that contain either subunit respond similarly to brief and low frequency synaptic 
inputs, however, α4 subunit containing receptors were less efficacious when 
exposed to prolonged tonic GABA or during repetitive stimulation, as may occur 
in seizures (Lagrange et al., 2007), therefore these subunit alterations are 
predicted to impair inhibitory function during epileptogenesis. Preventing SE-
mediated GABAAR α1 subunit reduction through viral-mediated gene transfer 
yielded a three-fold increase in time to first spontaneous seizure and a 39 
percent decrease in number of animals that went on to development 
spontaneous seizures in the first four weeks after SE (Raol et al., 2006a), 
thereby demonstrating the importance of GABAAR subunit composition in relation 
to development of spontaneous seizures. Taken together, these data suggest 
that post-SE elevation in BDNF may play a role in inhibitory function throughout 
epileptogenesis. 
BDNF seems to play a dual role in regulating inhibition. BDNF-mediated 
TrkB activation precedes elevation of GABAA α4 subunit expression in 
hippocampal neurons (Roberts et al., 2006). At the time of joining the laboratory, 
siRNA studies from the laboratory of our collaborator, Dr. Shelley Russek at 
Boston University, suggested that the BDNF-induced STAT3 phosphorylation 
and ICER induction in cultured hippocampal neurons is mediated by p75NTR 
signaling, suggesting that BDNF regulation of GABAA receptor α1 subunit 
expression is regulated by p75NTR signaling (personal comm. Russek, S.J). 
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Therefore, BDNF is able to activate different neurotrophin receptors to alter 
GABAAR subunit expression. Since proBDNF preferentially binds p75NTR and 
mBDNF preferentially binds TrkB, I hypothesized that BDNF processing may play 
an important role in post-SE neurotrophin receptor activation thereby affecting 
GABAAR subunit expression and later development of spontaneous seizures.  
 My first aim was to evaluate the relative expression of proBDNF and 
mBDNF in a model of TLE. Since the tools available at the time including 
commercially available antibodies lacked the required sensitivity and specificity to 
directly access the levels of proBDNF and mBDNF expression the first aim 
proved to a significant challenge.  Therefore, knock-in mice that express a 
hemagglutinin-tagged BDNF transgene under the control of endogenous bdnf 
promoters were probed for hemagglutinin to accurately assess the levels of pro 
and mBDNF following the induction of SE (Yang et al., 2009, figure 1.5). These 
knock-in mice provide enhanced sensitivity and specificity in analysis of pro- and 
mBDNF that would otherwise not have been feasible at the time, using BDNF 
antibody detection.  
The next question that was posed was which model of TLE to utilize to study 
pro- and mBDNF expression. Since the preliminary work for these studies utilized 
a pilocarpine model of TLE in rats it was decided to use a pilocarpine model of 
TLE in the knock-in mice. This model poses its own unique set of challenges 
since the mice are bred on to a C57BL/6J background thereby making it very 
challenging to induce SE in these mice which is more thoroughly described in 
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chapter II. The studies performed to elucidate regulation of pro- and mBDNF 
expression are described in chapter III. 
 
Figure 1.5. Generation of the BDNF-HA knockin mice. A) The strategy for 
generating the bdnf-HA knock-in mice. B) Southern blot analysis demonstrated 
that one endogenous bdnf allele was replaced by a bdnf-HA allele. C) ELISA 
analysis of total BDNF concentrations in hippocampi and cortices from WT (+/+) 
and bdnf-HA/+ mice. Error bars indicate s.e.m. (Yang et al., 2009) 
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CHAPTER II 
 
CHEMOCONVULSANT MODELS OF EPILEPSY IN C57BL/6J MICE 
 
Introduction 
Seizures in TLE are often refractory to anti-epileptic drugs. To develop 
effective therapies to treat TLE that reproduce the electrographic, behavioral, and 
neuropathological features of this neurological disorder, novel animal models are 
required. A few of the models that fit these criteria use chemoconvulsants either 
administered systemically or intracranially. One of the earliest chemoconvulsant 
models of TLE involved intra-amygdaloid injections of kainic acid, a cyclic analog 
of L-glutamate and an agonist of the ionotropic kainic acid and AMPA receptors, 
in Wistar rats (Ben-Ari and Lagowska, 1978; Ben-Ari et al., 1979). These animals 
developed behavioral seizures and neuropathological features that were similar 
to some patients with TLE, especially neurodegeneration mainly in the CA3 
region of the dorsal hippocampus. Soon after, another model using 
chemoconvulsants was developed through administration of pilocarpine, a 
cholinergic muscarinic agonist, in rats (Turski et al., 1983). Chemoconvulsant 
models in rats are very robust and have been used effectively for the past four 
decades. Unfortunately, the same cannot be said for chemoconvulsant models in 
mice.  
With the advent of transgenic mice, our ability to tease out the molecular 
mechanisms of a plethora of disease has made significant strides. The use of 
transgenic mice affords one the ability to better analyze and manipulate the 
molecular mechanisms of epileptogenesis. Knock-in mice that possess genes for 
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tagged fusion proteins allow one to study various difficult to probe proteins much 
more efficiently. Mice that possess inducible regulatory elements can provide 
temporal modulation of gene expression thereby minimizing off-target effects. 
The NIH Knockout Mouse Project has encouraged researchers to develop 
embryonic stem cell and knockout mice on a C57BL/6 background (International 
Mouse Knockout Consortium et al., 2007). The C57BL/6 strain of laboratory 
mouse consists of various heterogeneous substrains. The C57BL strain was 
established by C.C. Little in the 1920s. The C57BL/6 strain was separated from 
the parent line in the mid-1930s. Most importantly, the C57BL/6J substrain was 
established at Jackson laboratories and the C57BL/6N substrain was established 
at NIH in the 1940s and 1950s (Mekada et al., 2009). There are significant 
differences between these two substrains even though they were developed from 
the same parent line. The two substrains exhibit differences in behavioral profiles 
(Bryant et al., 2008) and responses to glucose (Freeman et al., 2006), alcohol 
(Khisti et al., 2006), drugs (Diwan and Blackman, 1980) and most importantly for 
these studies, chemoconvulsants (reviewed in Schauwecker, 2011). The issue is 
so pervasive that some labs have even reported variable sensitivities to 
pilocarpine in the same substrain housed in different barrier rooms (Müller et al., 
2009c).  
Systemic Pilocarpine-Induced SE in Mice 
 Several laboratories have published reports using systemic pilocarpine in 
mice to induce SE (Table 2.1). Many of them have used strains other than 
C57BL/6J, the strain most commonly used for transgenic mouse development. 
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The first report of pilocarpine administration in mice utilized Albino Swiss mice 
(Turski et al., 1984). The most common method for initiating pilocarpine-induced 
SE consists of pretreatment with a peripherally acting muscarinic acetylcholine 
receptor antagonist such as methyl scopolamine or atropine, minutes before 
injection of a single high dose of pilocarpine. If the mice survive SE, they go on to 
develop spontaneous recurrent seizures days later (Cavalheiro et al., 1996). 
Utilizing pilocarpine to induce SE in mice is challenging since mortality rates 
range from 25-100 percent depending on the dose and strain. Post-convulsion 
respiratory failure is the most common cause of acute death after pilocarpine 
administration (Boyd and Fulford, 1961). Many strains of mice exhibit neuronal 
cell death seven days after administration of pilocarpine. In C57BL/6J mice single 
high dose pilocarpine administration is able to produce significant neuronal cell 
lost in the hilus and CA3 subregions of the hippocampus at seven days 
(Schauwecker, 2012). Borges et al. conducted a thorough electrographic and 
histopathological study of pilocarpine-induced SE in C57BL/6J mice. They found 
that C57BL/6J mice suffered from high mortality (87/99); whereas, C57BL/6N 
mice possessed low mortality (15/26) when administered high-dose pilocarpine. 
In addition, C57BL/6J mice that underwent robust SE lasting longer than two 
hours showed significant hilar cell loss at 14 days, reactive microglia at four days, 
and gliosis after 14 days (Borges et al., 2003). The Loscher group has developed 
a method that utilizes repetitive dosing of lower amounts of pilocarpine in various 
strains to reduce mortality (Gröticke et al., 2007; Müller et al., 2009a, 2009b, 
2009c).   
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Year First 
Author
Last 
Author
Strain Age Time Scop Dose Scop Pilo Dose Time anti-
conv
Dose Anti-
conv
Onset SE % Survive & 
SE
Days til first SRS SRS Rate
1984 Turski Turski Albino Swiss Mice Adult male 
(25-30g)
30 min 1 mg/kg 325/350 mg/kg DZP 1hr 10 mg/kg 26.73 +/- 
12.7 min
75
1996 Cavalheiro Priel Albino Adult (25-
30g)
30 min 1 mg/kg 340 mg/kg 64 14.4 +/- 11.9 (4-
42)
2002 Shibley Smith C57BL/6Nhsd 
(Harlan)
Adult male 
(25-30g)
15-30 min 1 mg/kg 280-290 mg/kg - - 34.3 +/- 2.1 
min
53 13.1 +/- 2.4 (6-32) 0.18 +/- 0.04
2002 Troy Friedman 129:Balb/c Adult (24-
30g)
30 min 1 mg/kg with 
50 mg/kg 
phenytoin
320 mg/kg 2hr 10 mg/kg
C57BL/6 (JAX) 6-15wks 
(17-32g) or 
1+ yr (21-
32g)
15-30 min 2 mg/kg with 
2 mg/kb 
tertbutaline
247-335 mg/kg 1, 2, 2.5, 
4.5 hr
30 mg/kg 
PentoB
30-60 min 12
C57BL/6 (CRiver) 10wks (21-
25g)
15-30 min 2 mg/kg with 
2 mg/kb 
tertbutaline
300-315 mg/kg 4.5hr 30 mg/kg 
PentoB
Minutes 58
2004 Chen Becker C57BL/6 (CRiver) & 
Others
Adults 60-
70days (21-
37g)
30 min 1 mg/kg 272-340 mg/kg 2hr 0.1 mg/kg 81/ 42.9
C57BL/6Jlbm (RCC) 7wks - - 360 mg/kg DZP 30 min 10 mg/kg - 55 +/- 8
C57BL/6Jlbm x 
FVB/NJlbm (RCC)
7wks - - 360 mg/kg DZP 30 min 10 mg/kg - 71 +/- 5
FVB/NJlbm (RCC) 7wks - - 360 mg/kg DZP 30 min 10 mg/kg - 89 +/- 10
2004 Peng Houser C57BL/6 (Harlan) 6-8wks (20-
27g)
30 min 1 mg/kg 320-340 mg/kg 3hr 5 mg/kg 
DZP
2005 Hagihara Nakano C57BL/6 (Shizuoka 
Exp Animals)
5wks 15 min 5 mg/kg with 
atropine
300 mg/kg 2hr 10 mg/kg
2006 Overstreet Westbrook C57BL/6J Adult (2-4 
months)
30 min 1 mg/kg 300-325 mg/kg
2007 Groticke Loscher Female NMRI Adult (5-
6wks) 
30 min 1 mg/kg 100 mg/kg every 20 mins 
till SE
30, 90, 120 
mins
10 mg/kg 73-135 min ~70 (60-90%) 
or (40-60%)
2 wks post-
induction
2008 Porter Blendy 129 SVEV:C57BL/6 
(?)
Adult (3-
6months)
30 min 1 mg/kg 330 mg/kg 70 0.029 +/-0.019
2008 Volosin Friedman Sv129 (?) Adult (24-
30g)
30 min 1 mg/kg with 
50 mg/kg 
phenytoin
320 mg/kg 2hr 10 mg/kg
2009 Muller Loscher NMRI (Harlan-
Winkelmann, 
Borchen)
5-6wks 30 min 1 mg/kg 300 mg/kg 75 All of the 75%
C57BL/6NCrl Barrier 
room 8 (CRiver)
5wks 30 min 1 mg/kg 300 mg/kg / 100 mg/kg 
every 20 mins till SE (300-
1000)
90mins 10 mg/kg 60 min 80/80
C57BL/6NCrl Barrier 
room 9 (CRiver)
5wks 30 min 1 mg/kg 100 mg/kg every 20 mins 
till SE (300-1400)
90mins 10 mg/kg 26
C57BL/6Nhsd 
(Harlan)
5wks 30 min 1 mg/kg 350 mg/kg / 100 mg/kg 
every 20 mins till SE (300-
1000)
90mins 10 mg/kg 55 min 33/0
C57BL/6JOlaHsd 
(Harlan)
5wks 30 min 1 mg/kg 400 mg/kg / 100 mg/kg 
every 20 mins till SE (300-
1000)
90mins 10 mg/kg 75 min 20/0
2009 Sartori Langone Swiss 10-12wks 
(35-40g)
30 min 1 mg/kg 340 mg/kg None
2009 Zhang Tang Swiss Albino 25-30g 30 min 1 mg/kg 300 mg/kg - - - - - 0.71 +/- 1.01/day 
Type 1 cell loss; 0.43 
+/- 0.49/day type 2 
cell loss
2010 Li Obrietan C57BL/6 (Harlan) 8-9 wks 30 min 1 mg/kg with 
atropine
325 mg/kg 4 wks
Loscher
Wolffer
Dingledine
2004 Mohajeri
2003 Borges
2009 Muller
Table 2.1. Literature review of systemic pilocarpine-induced SE in mice.  
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Systemic Kainic Acid-Induced SE in Mice   
 The use of kainic acid as an epilepsy model in mice has proven to be 
problematic. Genetic background significantly affects both susceptibility to 
seizure induction, as well as the severity of damage caused by seizures. The 
C57BL/6J strain has been referred to as a “resistant strain” since high-dose 
systemic kainic acid administration fails to produce neuronal death (Schauwecker 
and Steward, 1997; Schauwecker et al., 2004; McLin and Steward, 2006). 
Unfortunately, the single high-dose method of induction is unable to produce 
spontaneous recurrent seizures and is therefore ineffective as a model of TLE 
(McKhann et al., 2003). More recently, a repetitive low-dose kainic acid regimen 
was developed and shown to reduce mortality from 21 to 6 percent with robust 
SE and decreased variability in seizure severity between animals (Tse et al., 
2014). More information is needed on the long-term electrographic and 
neuropathological characteristics of this model.  
Intrahippocampal Injection of Kainic Acid as a Model of SE in Mice 
 Much of the work using intrahippocampal injection of kainic acid was 
performed in various rat strains (Lévesque and Avoli, 2013). Bouilleret et al. 
conducted a thorough study of the electrographic and histological characteristics 
of unilateral intrahippocampal kainic acid administration in adult male Swiss 
mice. The intrahippocampal injection was followed by an initial partial complex 
SE followed by recurrent partial seizures. There was no observable behavioral 
correlate with the electrographic seizures in the chronic phase and lasted for up 
to eight months. Damage to the hippocampus evolved in a biphasic manner. The 
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initial injury is focused in the hilus and CA1 up to fifteen days after injection, but 
then spreads to the CA2 and CA3 seen along with granule cell dispersion up to 
30 days after injection (Bouilleret et al., 1999). Cell loss is observed in all 
hippocampal subfields up to 60 days after in both ipsi- and contralateral 
hippocampi (Miltiadous et al., 2013). One criticism of this model is the damage to 
the CA3, which is typically spared in human mesial TLE. Mossy fiber sprouting 
was observed in both the supragranular molecular layer and the infrapyramidal 
stratum oriens layers of the CA3 at 30 days via Timm’s staining (Bouilleret et al., 
1999). In another study, granule cell mossy fiber axons were observed near the 
granule cell somata at two weeks post-injection via zinc transporter 3 (ZnT-3) 
staining (Murphy et al., 2012). An increase in reactive astrocytes was observed in 
C57BL/6J mice at eight, 30, and 60 days after injection. Increased cell 
proliferation was observed via Ki67 immunostaining at eight and 30 days after 
injection (Miltiadous et al., 2013) and via Prox1 immunostaining at seven days 
(Murphy et al., 2012) and eight days (Miltiadous et al., 2013). In C57BL/6J mice 
kainic acid injection causes acute excitotoxic cellular degeneration with little to no 
detectable multi-unit activity at the site of injection. Population oscillations were 
generated by both ipsi- and contralateral hippocampi temporally corresponding to 
the initiation of SE. These oscillations are generated at a distance from the 
injection site with the activity being initiated in the CA3 or CA1 regions 
propagating to the dentate gyrus (Le Duigou et al., 2005). Inflammation and 
blood brain barrier disruption is also observed in C57BL/6J mice (Zattoni et al., 
2011).  
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Materials and Methods 
Induction of Status Epilepticus 
All animal procedures were performed in accordance with the University of 
Colorado Anschutz Medical Campus animal care and use committee’s 
regulations and NIH Guidelines, “Guide for the care and use of laboratory 
animals”. Animals were group housed with up to five age-matched liter mates in 
temperature and humidity controlled rooms with access to food and water ad 
libitum on a 12 hour light/dark cycle. 
Seizure Scale 
Seizures were scored according to a modified Racine scale (Borges et al., 
2003) as follows:  
Stage 0: normal activity  
Stage 1: rigid posture or immobility 
Stage 2: stiffened, extended, and often arched (Straub) tail 
Stage 3: partial body clonus, including forelimb or hindlimb clonus (seen rarely) 
 or head bobbing 
Stage 3.5: whole body continuous clonic seizures while retaining posture  
Stage 4: rearing  
Stage 4.5: severe whole body continuous clonic seizures while retaining posture  
Stage 5: rearing and falling  
Stage 6: tonic–clonic seizures with loss of posture or jumping 
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Single High Dose Pilocarpine 
SE was induced using a single high dose of pilocarpine adapted from 
(Shibley and Smith, 2002). The C57BL/6J mice (WT) were acquired from 
Jackson Labs and were received at five weeks of age and allowed to rest for one 
week prior to handling in order to acclimate to the environment and altitude. Six 
to eight week old WT (18-24g) were handled for at least one week prior to 
induction of SE to reduce stress produced by handling. The induction protocol 
was initiated between 7:00-8:00AM to minimize diurnal variation. The mice were 
transferred to the induction room, marked, weighed, and allowed to rest 
undisturbed for at least one hour. To block the peripheral muscarinic effects of 
pilocarpine, each mouse was given an i.p. injection of 1mg/kg scopolamine 
methyl bromide (Sigma) fifteen minutes before pilocarpine injection on the day of 
seizure induction. A dose of 280-320mg/kg pilocarpine in approximately 0.1mL 
sterile saline was administered. The animals underwent individual monitoring of 
behavioral seizures. The onset of SE was defined by the appearance of repeated 
behavioral seizures (stage 4 or higher with at least one seizure being 5 or 
higher). 
Repetitive Pilocarpine 
SE was induced using repetitive i.p. injections of pilocarpine as previously 
described (Müller et al., 2009c; Schauwecker, 2012). The C57BL/6J mice (WT) 
mice acquired from Jackson Labs were received at five weeks of age and 
allowed to rest for one week prior to handling in order to acclimate to the 
environment and altitude. The BDNF-HA mice were bred in the University of 
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Colorado Anschutz Medical Campus Vivarium. 6-8 week old WT and BDNF-HA 
mice (18-24g) were handled for at least one week prior to induction of SE to 
reduce stress produced by handling. The induction protocol was initiated 
between 7:00-8:00AM to minimize diurnal variation. The mice were transferred to 
the induction room, marked, weighed, and allowed to rest undisturbed for at least 
one hour. To block the peripheral muscarinic effects of pilocarpine, each mouse 
was given an i.p. injection of 1mg/kg scopolamine methyl bromide (Sigma) fifteen 
minutes before the first pilocarpine injection on the day of seizure induction. An 
initial dose of pilocarpine HCl (200mg/kg, Sigma) was given, then one hour after 
the first injection subsequent doses (100mg/kg) were given at 30 min intervals. 
The animals were group housed with up to five age-matched littermates and then 
separated into individual cages after the third injection for individual monitoring of 
behavioral seizures. Injections were discontinued at the onset of SE that was 
defined by the appearance of repeated behavioral seizures (stage 4 or higher 
with at least one seizure being 5 or higher). SE typically initiated approximately 
three hours after the first injection, requiring at least 3 injections (400mg/kg total 
dose) of pilocarpine with an average of 5 injections (600mg/kg total dose) of 
pilocarpine needed. SE persisted for at least 90 minutes.  
Intrahippocampal Kainic Acid  
Adult male mice were first anesthetized in 3-5 percent isoflurane and then 
transferred to a stereotaxic frame and maintained under 1-3 percent isoflurane. 
Animals were placed on a heat blanket to maintain normothermic conditions 
during the procedure. A small midline sagittal incision of approximately 1-1.5 cm 
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was made in the skin on the scalp to expose the skull. Six small holes were 
drilled over the areas of interest (bilateral frontal cortices, CA1 of the 
hippocampus for the depth electrode, and bilaterally behind lambda for reference 
and ground electrodes, and over the hippocampus for the guide cannula). A 33-
gauge steel locking infusion cannula (C315LI-SPCL with an 8mm projection, 
Plastics1, Roanoke, VA) was threaded into a 26-gauge guide cannula (C315GA-
SPC 8mm below pedestal, Plastics1, Roanoke, VA) at 2.0mm posterior and 
1.3mm lateral to bregma, and 1.5mm deep of the dura for hippocampal infusions 
in C57BL/6J mice. A dose of 0.2-0.6µg of kainic acid (Tocris Bioscience, Bristol, 
UK) in 0.1-0.2ul saline was administered at a rate of ~0.1µL/min in order to 
prevent tissue damage with the infusion cannula left in place for one minute post 
infusion to prevent backflow. Control animals were implanted and injected with 
the same volume of vehicle only. The twisted pair polyimide-coated stainless 
steel depth electrode (E363-3-2TW-SPC, 4mm length, Plastics1, Roanoke, VA) 
was placed at 2.8mm posterior and 2.0mm lateral to bregma, and 2.0mm deep of 
the dura based on (Häussler et al., 2012). The electrode assembly was fixed with 
dental cement and then anesthesia was discontinued. In short, electrodes were 
connected to a single brush 6-channel swivel commutator (SL6C/SB, Plastics1, 
Roanoke, VA) enabling free movement and EEG recordings were initiated 
immediately after cessation of anesthesia to monitor the duration and severity of 
SE. EEG signals synchronized with digital video were recorded using the Stellate 
Harmonie system (Natus Medical, San Carlos, CA). The EEG data were 
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collected with a sampling rate of 1,000 Hz and stored on a hard disk for offline 
analysis. 
Statistical Analysis 
Data are expressed as percentage of cohort with respect to each variable 
analyzed and plotted in bar chart format using Prism 5 (Graphpad, San Diego, 
CA) with n = the number of mice for a given variable. Statistical significance was 
determined by chi-squared test since the variables under the study are 
categorical. The analysis was performed on r x c contingency tables using Prism 
5 (Graphpad, San Diego, CA), where r represents the row consisting of the 
variable (category) analyzed and c represents the column consisting of the 
outcome of induction. Significance is reported at p<0.05 unless otherwise 
reported which results in rejection of the null hypothesis of no relation between 
the variables analyzed and the outcome of induction. 
Results 
 Much of the in vivo work in the laboratory has utilized the pilocarpine 
model of SE in Sprague-Dawley rats (Brooks-Kayal et al., 1998; Raol et al., 
2005, 2006a, 2006c; Lund et al., 2008). This model proves to be a reliable and 
consistent method of inducing SE in rats. Three of the most common models of 
SE in mice include systemic pilocarpine, systemic kainic acid, and 
intrahippocampal kainic acid. Unfortunately, mice treated with systemic kainic 
acid do not go on to develop spontaneous seizures therefore the method is ill-
suited as a model of TLE. Also, since the previous work that led to background 
for this project was conducted utilizing pilocarpine-induced SE it was thought that 
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the model should remain consistent. Since transgenic mice were necessary to 
answer some of the questions I proposed, I set out to develop a protocol for 
systemic administration of pilocarpine in C57BL/6J mice.  The initial trials 
compared a single high dose versus repetitive low dose regimen (RLDP). Based 
on a review of the literature (Table 2.1), potential dosages were determined 
which included 280mg/kg, 300mg/kg, and 320mg/kg. The repetitive dosing 
schema was initially based on work from the Loscher group (Gröticke et al., 
2007; Müller et al., 2009a, 2009b, 2009c). However, after discussions with many 
investigators the method was refined over the course of the year to consist of a 
loading dose of 200mg/kg with each subsequent 100mg/kg dose given after one 
hour at 30 minute intervals until the animal enters SE (personal comm. Houser, 
C.R; Shauwecker, P.E; Smith, B.N.). The refined repetitive low dose results are 
presented in figure 2.1 along with the single high dose results. The refined 
repetitive low dose was able to induce SE in 54 percent of the animals whereas a 
single 320mg/kg dose only induced 25 percent. The dose of pilocarpine did have 
an effect on SE outcome (p<0.05, Chi-squared test, 4x3 contingency table). 
Therefore, since the repetitive low dose protocol produced a higher percentage 
of animals undergoing SE it was chosen as the model of TLE for the subsequent 
studies.  
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Figure 2.1: Pilot data demonstrate that repetitive low-dose pilocarpine 
effectively induces SE in C57BL/6J mice. Graph of various dosing regimens of 
pilocarpine (280mg/kg, n=8; 300mg/kg, n=8; 320mg/kg*, n=8; 100mg/kg*, n=35) 
and outcomes in terms of survival and induction of SE. Note (*) indicates 
repetitive doses. 100mg/kg* utilized 200mg/kg for the first dose with 100mg/kg 
doses every 30 minutes until the onset of SE. Note that the repetitive low-dose 
pilocarpine protocol induces the greatest percent of animals achieving SE with 
the highest survival. NC: non-convulsive; SE: status epilepticus 
 
Since there are many factors that can affect the outcome of SE induction 
very small pilot studies were undertaken to determine the importance of these 
variables. Six variables were tested with groups of four animals. Since the pilot 
studies required testing six different variables only very small groups were 
allowed by the University of Colorado Anschutz Medical Campus IACUC, 
therefore statistics were not available for such small samples sizes. Since it had 
been previously reported that variable sensitivities to pilocarpine in the same 
substrain housed in different barrier rooms had been observed, the different 
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barrier rooms that ship to the university were tested (Müller et al., 2009c). There 
are two facilities that ship to include RB in Sacramento, CA and AX in Bar 
Harbor, ME. Four animals from RB03, RB04, RB05, AX4, AX8, and AX10 were 
subjected to RLDP and the barrier room did not appear to have an effect on SE 
outcome. In order to maintain consistency all mice for the studies were shipped 
from barrier room AX4. Mice of various ages were then evaluated from 6 weeks, 
7 weeks, 8 weeks, 10 weeks and 12 weeks. The most effective age range 
seemed to be 6-8 weeks of age, which is similar to the age range that proved 
most successful in a large cohort study (n=2413) of FVB mice (Buckmaster and 
Haney, 2012).  
Various dosing regimens were evaluated including 100mg/kg injections 
every 20 or 30 minutes with or without the first dose being a loading dose of 
200mg/kg. The loading dose with subsequent injections every 30 minutes 
seemed to provide the best SE induction outcome. This dosing regimen was 
suggested by Dr. Elyse Shauwecker, who studies the influence of strain on SE 
outcome and hippocampal neuronal death (Schauwecker and Steward, 1997; 
Schauwecker, 2000, 2003, 2011, 2012; Schauwecker et al., 2004). The severity 
of SE was then evaluated with repetitive stage 4 seizures, multiple stage 5-6 
seizures, or repetitive stage 4 seizures with isolated 5-6 seizures. Of these 
choices repetitive stage 4 seizures with isolated 5-6 seizures provided the best 
compromise between robust injury and mortality.  
The last variable that was evaluated with stress. Animal handling, duration 
of rest after transporting mice and group housing vs. individual housing was 
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probed. The most effective stress reduction measured appeared to be handling 
the mice for at least 10 days, resting the animals after transport for at least 60 
minutes, and group housing the animals for the first 3 injections. Stress has been 
shown to play an important role in vulnerability to epilepsy and depression. Fifty 
percent of rats subjected to social defeat, a model of stress, exhibited a reduced 
threshold for SE and accelerated epileptogenesis with a depression-like profile 
and cognitive deficits. This vulnerable population exhibited lowered serum BDNF 
levels with treatment with a BDNF analog preventing this phenotype (Becker et 
al., 2015).   
The following three figures collate SE induction outcome data from 2011-
2014 and probes the effect of year, genotype, and gender on the outcome of 
RLDP-induced SE. The data were analyzed using contingency tables and Chi-
squared test to determine if the variables altered the outcome of SE induction.   
In 2011, 36.7% of animals died (11/30), 23.3% were non-convulsive 
(7/30), and 40% developed SE and survived (12/30). In 2012, 33.3% of animals 
died (14/42), 30.95% were non-convulsive (13/42), and 35.7% developed SE and 
survived (15/42). In 2013, 28.2% of animals died (11/39), 46.2% were non-
convulsive (19/39), and 25.6% developed SE and survived (10/39). In 2014, 
18.4% of animals died (9/49), 32.6% were non-convulsive (16/49), and 50% 
developed SE and survived (24/49). The year of induction had no effect on SE 
induction outcome (p>0.05, Chi-squared test, 4x3 contingency table), therefore 
over the four years that these studies were conducted no improvement or 
worsening of SE outcome was observed (figure 2.2).  
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Figure 2.2: SE induction outcome data from 2011-2014. Graph of outcomes in 
terms of survival and induction of SE grouped by year. (2011, n=30; 2012, n=42; 
2013, n=39; 2014, n=49) The groups consist of all mice induced from 2011-2014 
with mixture of BDNF-HA and WT mostly males with some females included. NC: 
non-convulsive; SE: status epilepticus 
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Figure 2.3: SE induction outcome data with respect to genotype. Graph of 
outcomes in terms of survival and induction of SE grouped by genotype. 
(C57BL/6J, n=87; BDNF-HA, n=73) NC: non-convulsive; SE: status epilepticus 
 
 Certain studies were carried on in C57BL/6J WT animals and others were 
carried out in BDNF-HA knock-in mice on a C57BL/6J background. Of the 
C57BL/6J mice, 25.3% died during induction (22/87), 31% were non-convulsive 
(27/87), and 43.7% survived and developed SE (38/87). Of the BDNF-HA mice, 
31.5% died during induction (23/73), 37% were non-convulsive (27/73), and 
31.5% survived and developed SE (23/73). The genotype of the mouse 
subjected to RLDP had no effect on SE outcome (p>0.05, Chi-squared test, 2x3 
contingency table).  
0%
20%
40%
60%
80%
100%
C57BL/6J BDNF-HA
Dead
NC
SE
 
69 
 
 
Figure 2.4: SE induction outcome data with respect to gender. Graph of 
outcomes in terms of survival and induction of SE grouped by gender. (Male, 
n=141; Female, n=19) NC: non-convulsive; SE: status epilepticus 
 
Of the male mice, 31.9% died during induction (45/141), 30.5% were non-
convulsive (43/141), and 37.6% survived and developed SE (53/141). Of the 
female mice, 0% died during induction (0/19), 57.9% were non-convulsive 
(11/19), and 42.1% survived and developed SE (8/19). The effect of gender on 
induction outcome was analyzed in figure 2.4. Gender had an effect on SE 
induction outcome (p<0.05, Chi-squared test, 2x3 contingency table). An 
increased sample size would help clarify any gender-based differences. Only 
male mice were analyzed since there is a known variation in GABAR subunit 
expression and seizure susceptibility during the estrous cycle in female rodents 
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(Smith et al., 1998). Sex hormones have also been shown to regulate expression 
of BDNF (Scharfman and Maclusky, 2014).  
Since the future aims of chapter II involve complex transgenic breeding 
schemes with tamoxifen-induced knockouts, it was necessary to develop an even 
more robust model of TLE. The intrahippocampal kainic acid model produces 
robust SE with almost all of the mice going on to develop spontaneous seizures. 
A proof of concept study was conducted with a group of three animals (10-12 
weeks of age) to determine the proper dose of kainic acid required to elicit robust 
SE and development of spontaneous seizures. The model is typically 
characterized by spontaneous electrographic seizures characterized by 
hippocampal paroxysmal discharges lasting longer than 20 s mostly ipsilateral to 
the injection without a behavioral correlate (Bouilleret et al., 1999; Riban et al., 
2002; Zattoni et al., 2011); however, a subset of animals developed occasional 
robust behavioral seizures up to stage six on the modified Racine scale (figure 
2.5). The results from the pilot study found that all mice receiving 100nL of 20mM 
kainic acid (n=3) had robust SE consisting of repetitive stage 5-6 seizures on the 
modified racine scale. These mice possessed a latent period of approximately 21 
days with approximately 1-20 electrographic seizures occurring every hour (3/3) 
with isolated electroclinical seizures (2/3) ranging from stage 4-6 on the modified 
racine scale.  
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Figure 2.5: Intrahippocampal kainic acid model of epileptogenesis in 
C57BL/6J mice. Representative EEG traces from A) saline injected control 
mouse; B) mouse acutely after kainic acid injection and shortly arousing from 
anesthesia associated with stage six tonic-clonic behavioral seizure with loss of 
posture and jumping; C) typical spontaneous recurrent electroclinical seizure in a 
chronic kainic acid-injected mouse (over three weeks after SE) correlated with 
stage six behavioral seizure with whole-body clonic activity, rearing, loss of 
posture and jumping, and D) a focal spontaneous recurrent subclinical seizure in 
a chronic kainic acid-injected mouse that had no perceptible correlated behavior 
with peak amplitude three times that of baseline, high voltage sharp waves 
followed by higher frequency lower voltage rhythmic activity with clear evolution. 
EEG traces recorded at 2000Hz on Stellate Harmonie EEG monitoring system. 
Using stainless steel subdural screws implanted above both motor cortices to 
record cortex and polyimide-coated stainless steel twisted pairs implanted in to 
the ipsilateral CA1 to record hippocampus. 
 
Discussion 
 
One of the main difficulties in using animal models of TLE is the issue of 
consistency. The Neurocritical Care Society guidelines define SE as “5 minutes 
or more of (i) continuous clinical and/or electrographic seizure activity or (ii) 
recurrent seizure activity without recovery (returning to baseline) between 
seizures” (Brophy et al., 2012). Unfortunately, the definition for SE in animal 
models is not so clear, making it challenging to make use of these models in a 
reliable manner. Much of the seizure staging criteria is based on the Racine 
scale; however, defining the initiation of SE is less clear-cut. Adding more 
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complexity to the problem, chemoconvulsant sensitivity can vary not only by 
substrain but even by barrier room (Müller et al., 2009c). Susceptibility to 
chemoconvulsants can even be altered by a few crosses between mice from the 
same substrain that reside in different barrier rooms (Bankstahl et al., 2012). 
Even among the same model, small variations in technique can produce 
substantial differences in the electrographic and neuropathological sequelae of 
the disease (Benkovic et al., 2004). An important issue moving to the forefront of 
the field involves ensuring consistency across laboratories using the same model 
to ensure the reproducibility of scientific findings.  
 Mouse models of epilepsy have come a long way but are still lacking for 
the most commonly used genetic background for transgenic mice, C57BL/6J. 
Many laboratories produce F1 crosses with the C57BL/6N substrain to introduce 
seizure susceptibility traits and refer to them as C57BL/6 or B6 mice when 
reported in the literature (Schauwecker, 2011). It is unclear what effect this has 
on the outcomes and findings of the studies, making reproducibility challenging at 
best. Therefore, it is important to discuss any finding in the context of the model 
from which it was obtained. The systemic pilocarpine model yielded anywhere 
from 25-50 percent of the mice undergoing and surviving SE. There was no 
effect of year or genotype on SE outcome. The differences in SE induction 
outcome between male and female mice might be due to the effect of 
reproductive hormones on brain excitability and seizures which is well-described 
in the literature (Scharfman and MacLusky, 2006; Verrotti et al., 2007).  
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Future Directions 
The future directions for this project contain very challenging breeding 
schemes with lines that significantly impact the cost and pace at which the 
experiments can be conducted (see chapter IV). Since the repetitive pilocarpine 
model of SE has yielded only approximately 30 percent of the animals 
undergoing SE and surviving, I have adapted a method of intrahippocampal 
kainic acid that can be used to produce robust SE in C57BL/6J mice in addition 
to subsequent spontaneous recurrent seizures. One may think that requiring 
surgery for every single mouse may negatively impact the speed at which the 
experiments can be completed; however, consistency is the main advantage to 
the model. Once proficient, the total surgery takes about 30-45 minutes and the 
animals undergo video-EEG monitoring. The systemic pilocarpine model in mice 
requires at least eight hours with the ability to monitor only four actively seizing 
animals at a time. In the same timeframe one would be able to complete 
approximately ten surgeries with almost all of the animals proceeding to SE and 
spontaneous seizure within a few weeks. Some mouse models of TLE, such as 
intrahippocampal kainic acid, there exists a prominent electro-behavioral 
disassociation (Bouilleret et al., 1999) thereby, necessitating the use of EEG to 
optimally determine the course of SE and epileptogenesis (figure 2.5D). 
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CHAPTER III 
 
RAPID INCREASES IN PROBDNF AFTER PILOCARPINE-INDUCED STATUS 
EPILEPTICUS IN MICE ARE ASSOCIATED WITH REDUCED PROBDNF 
CLEAVAGE MACHINERY 
Introduction 
Several studies have demonstrated that a significant portion of BDNF protein 
is secreted as proBDNF and cleaved extracellularly via the tPA/plasmin 
proteolytic cascade (Lee et al., 2001; Pang et al., 2004; Nagappan et al., 2009). 
Theta burst stimulation (14,400 pulses, 60 min) triggers simultaneous release of 
proBDNF and tPA to generate mBDNF extracellularly in vitro suggesting that this 
could occur as a result of repeated neuronal firing as occurs during a seizure 
episode (Nagappan et al., 2009). However, the in vivo effects of acute seizures 
on the expression of proBDNF and mBDNF has not been fully elucidated. 
The first reports of BDNF expression after limbic seizures was published in 
1991 (Gall et al., 1991; Isackson et al., 1991), since that time numerous reports 
suggest that BDNF levels are increased in the hippocampus in rats after seizures 
induced by kindling (mRNA) (Ernfors et al., 1991), electroconvulsive shock 
(mRNA) (Altar et al., 2004), kainic acid (protein) (Rudge et al., 1998), and 
pilocarpine (mRNA) (Roberts et al., 2006). Chronic intrahippocampal injection of 
BDNF results in spontaneous limbic seizures through TrkB signaling in adult 
animals, suggesting that high levels of BDNF are sufficient to produce 
epileptogenesis (Scharfman et al., 2002). To further support the role of BDNF in 
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epileptogenesis, knockdown of BDNF reduced development of kindling (Kokaia 
et al., 1995).  
BDNF has multiple and complex effects that may contribute to 
epileptogenesis in a number of ways. Since BDNF plays an important role in 
synaptogenesis leading to a significant interest in its role in mossy fiber sprouting 
(Patel and McNamara, 1995; Lowenstein and Arsenault, 1996; McAllister et al., 
1997; Bender et al., 1998; Labelle and Leclerc, 2000). BDNF was shown to be 
necessary and sufficient to induce mossy fiber sprouting in ex vivo hippocampal 
cultures through activation of TrkB (Koyama et al., 2004). Most recently, 
transgenic mice that overexpress BDNF in the hippocampus exhibit expansion of 
the dentate mossy fiber-CA3 projections. In addition, the mice demonstrated 
increased seizures susceptibility to subconvulsive doses of pilocarpine 
suggesting that sustained increases in endogenous BDNF may modify the 
dentate structural organization over time (Isgor et al., 2015). Inhibition of the 
mTOR pathway, which is downstream of TrkB activation, is able to prevent 
mossy fiber sprouting in pilocarpine-induced SE mice and rats (Buckmaster et 
al., 2009; Buckmaster and Lew, 2011; Heng et al., 2013). It is presumed that the 
pro-epileptogenic effects of BDNF act primarily through TrkB receptor activation 
since neuronal-specific conditional knockout of TrkB is protective against 
epileptogenesis, transient inhibition of TrkB phosphorylation by a chemical-
genetic approach prevents development of spontaneous recurrent seizures in an 
intra-amygdalar kainic acid model, and increased TrkB receptor activation in TLE 
models results in enhanced epileptogenesis (He et al., 2004; Heinrich et al., 
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2011; Liu et al., 2013). However, other studies provide evidence for BDNF as an 
anti-epileptogenic mediator, demonstrating that chronic intrahippocampal infusion 
of BDNF results in enhanced resistance to kindling (Larmet et al., 1995; Reibel et 
al., 2000). BDNF may exhibit a neuroprotective effect in the developing brain 
since i.c.v. infusion of BDNF antisense oligonucleotides in juvenile rats subjected 
to kainic acid-induced seizures increases loss of CA1 and CA3 pyramidal cell 
and hilar interneurons when compared to age-matched untreated kainic acid 
injected controls (Tandon et al., 1999). Heterozygous BDNF mice exhibit 
increased resistance to kainic acid induced limbic seizures and increased 
resistance to amygdala kindling, however they also exhibited increased 
susceptibility to pilocarpine induced limbic seizures. Therefore, decreased BDNF 
expression is able to confer resistance to some types of seizures but not others 
(Kokaia et al., 1995; Barton and Shannon, 2005). In addition, low dose 
administration of BDNF by encapsulated BDNF-secreting cells implanted into the 
striatum of rats subjected to kainic acid-induced seizures imparted a 
neuroprotective effect on CA1 and CA3 pyramidal cells with an observed 
amelioration in SE severity and abnormal spikes observed 7 days after kainic 
acid (Kuramoto et al., 2010). Notably, these studies did not differentiate between 
the effects of different BDNF isoforms, and thus these contrasting findings may 
be due, in part, to the differential actions of proBDNF and mBDNF during 
epileptogenesis. 
A potential role for proneurotrophins in epileptogenesis is starting to emerge. 
Much of the proneurotrophins seizure literature involves proNGF-mediated 
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apoptosis (Roux et al., 1999). Few studies have examined changes in proBDNF. 
ProBDNF immunostaining was observed in pilocarpine induced-SE rats at one 
and three days after injury in hippocampal neurons. Increased binding of 
proBDNF to p75NTR with decreased TrkB phosphorylation after pilocarpine 
induced SE in rats resulted in elevated levels of neuronal death (Unsain et al., 
2008). Pilocarpine induced SE also increased the expression of p75NTR in rats 
through expression of the inflammatory cytokine IL-1β (Roux et al., 1999; Troy et 
al., 2002; Choi and Friedman, 2009, 2014). P75NTR expression was observed in 
cells that were positive for TUNEL staining after pilocarpine induced SE in rats, 
suggesting a link between p75NTR expression and cell death (Roux et al., 1999).  
P75NTR constitutive knockouts on a mixed 129/Balb/c background were subjected 
to pilocarpine induced SE and exhibited no activation of caspase-3, a marker of 
apoptosis, and sharply attenuated Fluro-jade B labeling by as much as 80 
percent, a marker of degenerating neurons (Troy et al., 2002). Therefore, 
activation of p75NTR, the high affinity receptor for proneurotrophins, plays an 
important role in cell death after SE.  
Recent studies have focused on neurotrophin processing after seizure. 
MMP-9 may have an impact on PTZ kindling through cleavage of proBDNF to 
mBDNF in the hippocampus evident from studies where bilateral injection of 
proBDNF into the dentate gyrus of wild-type (WT) mice enhanced kindling, 
whereas MMP-9 -/- mice had an equivalent response to PTZ kindling (Mizoguchi 
et al., 2011). Enhancing cleavage of pro-nerve growth factor (proNGF) to 
generate mature NGF provides neuroprotection after administration of kainic acid 
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to organotypic slice cultures (Le and Friedman, 2012). In rodents, increases in 
BDNF mRNA occur as early as three hours after pilocarpine-induced SE (rats) 
(Mudò et al., 1996), and increased proBDNF protein can be detected within 24 
hours of SE (rats and mice) (Volosin et al., 2008; VonDran et al., 2014).  
Levels of neurotrophin cleavage enzymes have also been shown to increase 
after seizure. Kainic acid-induced seizures cause furin and PC1 mRNA levels to 
increase concomitantly with BDNF (Meyer et al., 1996) and levels of proprotein 
convertase one (PC1) mRNA increase with BDNF mRNA after pilocarpine-
induced seizures (Marcinkiewicz et al., 1997). In the PTZ model of seizure and in 
the kindling model, tPA was induced acutely after seizure onset (Qian et al., 
1993). Levels of tPA protein expression are elevated in TLE patients with 
hippocampal sclerosis, especially in pyramidal neurons of CA1 and CA3, granule 
cells of the DG, GFAP+ reactive astrocytes, and microglia (Iyer et al., 2010). 
Plasminogen mRNA is strongly induced six hours after kainic acid injection in 
adult mice in the CA3 region of the hippocampus, the region of greatest neural 
degeneration (Matsuoka et al., 1998). However, the functional effects of the 
increased cleavage enzymes on neuronal survival after SE are still controversial. 
TPA-/- mice exhibit stronger proBDNF immunoreactivity in the hippocampus, 
suggesting that tPA cleaves proBDNF in vivo (Pang et al., 2004), and these mice 
possess a higher threshold for onset of seizures after systemic delivery of kainic 
acid or PTZ, however this may be due to the ability of tPA to potentiate NMDA 
signaling (Tsirka et al., 1995; Nicole et al., 2001). TPA is able to modulate NMDA 
receptor function through at least three possible mechanisms, a non-proteolytic 
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mechanism by interacting with NR2B, a proteolytic mechanism by cleavage of 
the NR1 subunit of NMDA receptor through plasmin, or through interactions with 
a low-density lipoprotein receptor (Nicole et al., 2001; Matys and Strickland, 
2003; Vivien et al., 2003; Pawlak et al., 2005; Samson et al., 2008). In addition, 
inhibition of plasmin by α2 antiplasmin yields resistance to kainic acid-induced 
excitotoxic neuronal degeneration (Tsirka et al., 1997). On the other hand, tPA 
has been shown to protect hippocampal neurons in culture from hypoxia-induced 
cell death paradigm and kainic acid-induced neuronal injury (Flavin and Zhao, 
2001; Echeverry et al., 2010). Further, Kim et al. demonstrated cytoprotective 
effects of intracerebroventricular tPA injection thirty minutes before kainic acid 
induction of seizure in adult rats (Kim et al., 1999). TPA has been implicated in 
mossy fiber sprouting, a hallmark of TLE, since TPA -/- mice exhibit decreased 
mossy fiber sprouting after intra-amygdala kainic acid induced seizures (Wu et 
al., 2000).  
More recently, it has been reported that high dose proBDNF applied to 
cultured hippocampal neurons may cause alterations in GABAergic 
neurotransmission by promoting GABAAR endocytosis and degradation through 
activation of the RhoA-Rock-PTEN pathway, and may contribute to repression of 
GABAAR synthesis through activation of the JAK/STAT pathway (Riffault et al., 
2014). Addition of exogenous BDNF to primary hippocampal neuronal cultures 
rapidly increases STAT3 phosphorylation (Lund et al., 2008). BDNF-dependent 
activation of the JAK/STAT pathway in dentate gyrus of rats drives a decrease in 
the mRNA of the α1 subunit of GABAR acutely after SE onset (Lund et al., 2008; 
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Grabenstatter et al., 2014), suggesting that BDNF-induced activation of the 
JAK/STAT pathway occurs rapidly after SE onset. Alterations in GABAA receptor 
subunit composition and localization can have significant effects on synaptic 
inhibition through diminished sensitivity to benzodiazepines, enhanced sensitivity 
to zinc blockade, reduced neurosteroid modulation, and diminished phasic 
inhibition in dendrites (Buhl et al., 1996; Gibbs et al., 1997; Cohen et al., 2003; 
Sperk et al., 2007). α1β3γ2L and α4β3γ2L subunit containing GABAARs possess 
different functional characteristics. Receptors that contain either subunit respond 
similarly to brief and low frequency synaptic inputs, however, α4 subunit 
containing receptors were less efficacious when exposed to prolonged tonic 
GABA or during repetitive stimulation, as may occur in seizures (Lagrange et al., 
2007). In addition, α4 containing subunits are less sensitive to benzodiazepine-
mediated allosteric inhibition, a common class of anti-seizure drugs. Preventing 
SE-mediated GABAAR α1 subunit reduction through viral-mediated gene transfer 
yielded a three-fold increase in time to first spontaneous seizure and a 39 
percent decrease in number of animals that went on to development 
spontaneous seizures in the first four weeks after SE (Raol et al., 2006a). Since 
proBDNF has been shown to activate the JAK/STAT pathway leading to 
repression of GABAAR synthesis and repression of α1 subunit expression; 
proBDNF may play an important role in the breakdown of inhibition observed 
after SE.  
The relative contributions of proBDNF and mBDNF in epileptogenesis are 
thus complex and have yet to be fully elucidated. Current methods, including 
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commercially available antibodies lack the required sensitivity and specificity to 
accurately access the relative levels of proBDNF and mBDNF expression.  
Therefore, knock-in mice that express a hemagglutinin-tagged BDNF transgene 
under the control of endogenous bdnf promoters were used in order to accurately 
assess the levels of BDNF following the induction of SE (Yang et al., 2009). 
These knock-in mice provide enhanced sensitivity and specificity in analysis of 
pro- and mBDNF that would otherwise not be feasible using antibody detection. 
Expression of various members of the cleavage machinery were also be 
evaluated via western blot. Evaluating the expression of these enzymes and 
inhibitors will provide some information on cleavage activity that could be 
followed up with functional activity assays. The following studies demonstrate 
that within the first 24 hours after pilocarpine-induced SE there is an acute 
increase of proBDNF levels in the absence of measurable increases in mBDNF. 
This finding, in combination with our demonstration of altered expression of 
cleavage enzymes, tPA and PAI-1, is consistent with reduced BDNF cleavage 
acutely after SE that suggest that proBDNF may be the initial neurotrophin signal 
driving cell signaling during early epileptogenesis. 
Materials and Methods 
Induction of Status Epilepticus 
All animal procedures were performed in accordance with the University of 
Colorado Anschutz Medical Campus animal care and use committee’s 
regulations and NIH Guidelines, “Guide for the care and use of laboratory 
animals”. Animals were group housed with up to five age-matched liter mates in 
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temperature and humidity controlled rooms with access to food and water ad 
libitum on a 12 hour light/dark cycle.  
Knock-in mice that express a bdnf allele with a hemagglutinin tag added to 
the C-terminus of the murine coding exon of BDNF (BDNF-HA) were generously 
provided by the Hempstead group (Weill Cornell Medical College) (Yang et al., 
2009). The use of heterozygous BDNF-HA mice allowed for more specific and 
sensitive analysis of BDNF levels than was possible using currently available 
BDNF antibodies. BDNF-HA mice were backcrossed on a C57BL/6J background 
for more than ten generations and wild-type mice (+/+, C57BL/6J, Jackson Labs) 
were utilized for the protease machinery studies. SE was induced using repetitive 
i.p. injections of pilocarpine as previously described (Müller et al., 2009c, see 
chapter II). The mice acquired from Jackson Labs were received at five weeks of 
age and allowed to rest for one week prior to handling in order to acclimate to the 
environment and altitude. Six to eight week old WT and BDNF-HA mice (18-24g) 
were handled for at least one week prior to induction of SE to the reduce stress 
produced by handling. The induction protocol was initiated between 7:00-8:00AM 
to minimize diurnal variation. The mice were transferred to the induction room, 
marked, weighed, and allowed to rest undisturbed for at least one hour. To block 
the peripheral muscarinic effects of pilocarpine, each mouse was given an i.p. 
injection of 1mg/kg scopolamine methyl bromide (Sigma) fifteen minutes before 
the first pilocarpine injection on the day of seizure induction. An initial dose of 
pilocarpine HCl (200mg/kg, Sigma) was given, then one hour after the first 
injection subsequent doses (100mg/kg) were given at 30 min intervals. The 
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animals were group housed with up to five age-matched littermates and then 
separated into individual cages after the third injection for individual monitoring of 
behavioral seizures. Injections were discontinued at the onset of SE that was 
defined by the appearance of repeated behavioral seizures (stage 4 or higher 
with at least one seizure being 5 or higher) according to a modified Racine scale 
(Borges et al., 2003):  
Stage 0: normal activity  
Stage 1: rigid posture or immobility 
Stage 2: stiffened, extended, and often arched (Straub) tail 
Stage 3: partial body clonus, including forelimb or hindlimb clonus (seen rarely)  
or head bobbing 
Stage 3.5: whole body continuous clonic seizures while retaining posture  
Stage 4: rearing  
Stage 4.5: severe whole body continuous clonic seizures while retaining 
posture  
Stage 5: rearing and falling  
Stage 6: tonic–clonic seizures with loss of posture or jumping  
SE typically initiated approximately three hours after the first injection 
requiring at least three injections (400mg/kg total dose) of pilocarpine with an 
average of five injections (600mg/kg total dose) of pilocarpine needed. SE 
persisted for at least 90 minutes with approximately 30 percent of animals 
successfully undergoing SE and surviving until their respective time points. 
Control mice were given injections of saline at identical time intervals. Mice that 
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were sacrificed at 24 hours were returned to their housing room and given free 
access to water, Gatorade, and moistened chow with equal parts sucrose. Mice 
were sacrificed with rapid isoflorane-induced anesthesia followed by decapitation 
at three or 24 hours after SE onset and tissue was collected for western blotting 
via rapid hippocampal dissection or immunohistochemistry via intracardial 
perfusion. The tissue for western blot was collected via rapid hippocampal 
dissection in ice cold PBS containing phosphatase inhibitors (phosphatase 
inhibitor cocktail 2, P5726, Sigma) and frozen on dry ice. The samples were 
stored at -80°C until lysate preparation. For immunohistochemistry mice were 
sacrificed at three hours after SE onset by deep anesthesia with 
ketamine/xylazine and inhaled isoflurane by rapid perfusion with ice cold PBS 
followed by 4% paraformaldehyde in phosphate buffer pH 7.4 (PB). The brains 
were dissected out, postfixed overnight in 4% paraformaldehyde and underwent 
cryoprotection in 30% sucrose in PBS, and were then stored at -80°C in Tissue-
Tek® O.C.T. Compound (Sakura Finetek, Torrance, CA) until sectioning. 
Western Blotting 
The frozen hippocampi were lysed in RIPA buffer (50mM Tris-HCl, pH 7.4, 
150mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1mM EDTA) with 10mM 
phenylmethylsulfonyl fluoride, 10mM sodium orthovanadate, 10mM sodium 
fluoride, phosphatase inhibitor cocktail 2 (1:250) and protease inhibitor cocktail 
(1:250, P8340, Sigma) using an ultrasonic sonifier. Then, samples were gently 
shaken at 4°C for 30 minutes and centrifuged at 14,000 x g for 30 minutes at 
4°C. The supernatants were reserved, aliquoted, and stored at -80°C until 
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sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). After 
gel transfer, the nitrocellulose membranes were blocked with 5% milk (furin and 
MMP-9 which were blocked with 5% non-fat dry milk, 2% BSA, 4% FBS, 4% 
normal horse serum, and 4% normal goat serum). The blots probed with the anti-
HA and BDNF antibody were first washed with Tris buffered saline with Tween-
20 (TBST, 50mM Tris-Base, 150mM NaCl, 0.05% Tween-20, pH 7.6) and then 
fixed with 2.5% glutaraldehyde in PBS, washed twice with PBS, washed twice 
with TBST, and then blocked with 5% milk in TBST. All membranes were 
incubated overnight at 4°C with their respective primary antibody in diluted 
blocking buffer. The following antibodies and concentrations were used: mouse 
monoclonal HA.11 clone 16B12 antibody (1:3,000, MMS-101P, Covance), mouse 
monoclonal proBDNF antibody (1:1000, H10001G-MA, GeneCopoeia), rabbit 
monoclonal BDNF antibody (1:1000, ab108383, Abcam), rabbit polyclonal to 
alpha-2 antiplasmin (1:2,000, ab62771, Abcam), rabbit polyclonal furin antibody 
(1:1,000, sc-20801, Santa Cruz), rabbit polyclonal MMP-9 antibody (1:2,000, 
AB13458, Millipore), sheep polyclonal neuroserpin antibody (1:2,000, 
SASMNSP-GF-HT, Molecular Innovations), rabbit polyclonal PAI-1 antibody 
(1:1,000, ASMPAI-GF-HT, Molecular Innovations), rabbit polyclonal plasminogen 
antibody (1:3,000, ASMPLG-GF-HT, Molecular Innovations), sheep polyclonal 
tPA antibody (1:500, SASTPA-GF-HT, Molecular Innovations), and rabbit 
polyclonal TIMP-1 antibody (1:1,000, AB770, Millipore). Following incubation with 
the appropriate secondary antibody, membranes were incubated with 
SuperSignal West Dura Chemiluminescent Substrate (Pierce) with the HA blots 
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being enhanced with Lumigen TMA-6 (Lumigen). Blots were stripped with 50mM 
glycine pH 2.3 and reprobed with other primary antibodies or Actin (1:20,000-
80,000, A2066, Sigma). Western blotting results presented include 
representative images of the blots run in duplicate and adjusted for contrast and 
the densitometry quantitation of each band normalized to actin that was used as 
a loading control to ensure consistent protein amounts were loaded across 
samples using FIJI (Schindelin et al., 2012). The average of the normalized 
densitometry measurements for the control group was considered 100%. 
Immunohistochemistry 
Brains were sectioned at 30 μm into cryoprotectant (30% sucrose, 30% 
ethylene glycol, and 0.1M phosphate buffer (PB)) and stored at -20°C for floating 
section staining. Sections were washed in PBS several times and then blocked 
with 3% BSA, 3% normal goat serum, and 3% normal donkey serum with 0.1% 
Triton X-100 in PBS for one hour at room temperature and then incubated 
overnight at 4°C with rabbit polyclonal HA antibody (1:500, A6908, Sigma) in 
combination with chicken polyclonal MAP2 antibody (1:1000, ab5392, Abcam) 
and guinea pig polyclonal GFAP antibody (1:500, 174004, Synaptic Systems). 
After primary antibody washing, sections were incubated for one hour with a 
biotinylated goat anti-rabbit IgG secondary antibody (1:400, 111-065-144, 
Jackson Immunoresearch), a goat anti-chicken IgY Alexa Fluor 568, and donkey 
anti-guinea pig IgG Alexa Fluor 647 to detect MAP2 and GFAP, respectively. 
Sections were subsequently incubated for one hour with Alexa Fluor 488-
Streptavidin (1:800, 016-580-084, Jackson Immunoresearch) to visualize the HA 
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tag. The sections were mounted on glass slides with VECTASHIELD Mounting 
Medium with DAPI (Vector Labs), coverslipped, and sealed.  
Confocal Microscopy 
Imaging experiments were performed in the University of Colorado Anschutz 
Medical Campus Advance Light Microscopy Core supported in part by Rocky 
Mountain Neurological Disorders Core Grant Number P30NS048154 and by 
NIH/NCRR Colorado CTSI Grant Number UL1 RR025780. Slide-mounted 
sections of immunolabeled hippocampi were viewed on an inverted microscope 
(Axio Examiner Z1, Carl Zeiss) equipped with Plan-Apochromat 20x (0.8 NA) or 
63x (oil differential interference contrast; 1.4 NA) objectives and attached to a 
spectral confocal laser system (LSM 780, Carl Zeiss) powered by ZEN 2012 
software (Carl Zeiss). The tissue was scanned at room temperature with a 
tunable infrared Coherent Chameleon Ultra II laser tuned to 800nm to detect 
DAPI staining and 488-, 561-, and 633-nm laser lines to detect the Alexa 
fluorophores 488, 568, and 647, respectively. Images were acquired as z-stacks 
using sequential line (mean of four) scanning. Colocalization of three 
fluorophores with DAPI was qualitatively assessed in the x, y, and z planes of 
each optical section. Average projection images of 5 optical slices spaced 2um in 
the z-axis were produced and minimal adjustments to image contrast and 
intensity were made in FIJI (Schindelin et al., 2012) using the levels or 
contrast/brightness functions. All brains and sections were processed in parallel 
with images acquired and analyzed in a consistent manner between SE and 
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control animals. Images were arranged and annotated using Adobe Illustrator 
(Adobe Corporation). 
Statistical Analysis 
Data are expressed as mean ± SEM and plotted in bar chart format using 
Prism 5 (Graphpad, San Diego, CA) with n = the number of mice for a given 
experimental group. Statistical significance was determined by unpaired two-
tailed student’s t-test using Prism 5 (Graphpad, San Diego, CA) since the data 
consist of two independent populations with normal distributions and form to 
required assumptions. Significance is reported at p<0.05. 
Results 
Relative levels of pro- and mBDNF protein expression were assessed in 
age-matched pilocarpine- and saline-treated BDNF-HA mice. The use of BDNF-
HA mice allowed a more specific and sensitive analysis of BDNF levels than 
what is possible using currently available BDNF antibodies. Tissue of vehicle-
treated controls or mice subjected to pilocarpine induced SE was collected at 
three and 24 hours after SE onset. Western blot analysis showed a significant 
increase in HA-immunoreactivity (control- 100.0 ± 20.5, N=3 vs SE- 300.4 ± 37.4 
N=6; t-test p<0.05) representing proBDNF (34 kD), this increase was observed 
as early as three hours after SE induction (figure 3.1a). No difference in HA-
immunoreactivity was observed for the mBDNF band (14 kD) between the SE 
and control animals (control: 100.0 ±12.2, N=3 vs SE: 96.4 ±5.8; N=6; t-test 
p>0.05). A significant increase in proBDNF immunoreactivity (control- 100.0 ± 
29.3 N=3 vs SE- 610.1 ± 89.7 N=6; p<0.005) was also observed 24 hours after 
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SE (figure 3.1b) but mBDNF immunoreactivity was not different (control- 100.0 
±4.9 N=3 vs SE- 98.5 ±5.0 N=6, t-test p>0.05).  Together, these data 
demonstrate a significant increase in the levels of proBDNF that occur acutely 
after pilocarpine-induced SE while the protein levels of mBDNF remain 
unchanged. The results in figure 3.1 were confirmed through additional western 
blots using commercially available antibodies raised against proBDNF and 
mBDNF.   
A significant increase in the immunoreactivity of proBDNF was observed at 
three (figure 3.2a; control-100.0 ± 10.6 N=5 vs SE- 326.4 ± 12.2 N=5, t-test 
p<0.0005) and 24 hours (figure 3.2b; 100.0 ± 16.6 N=5 vs 180.4 ± 18.0 N=5, t-
test p<0.05) after SE onset, while mBDNF immunoreactivity was unchanged (3h- 
figure 3.2c; control-100.0 ± 18.9 N=5 vs SE- 110.8 ± 10.8 N=5, t-test p>0.05; 
24h- figure 3d; control-100.0 ± 15.6 N=4 vs SE- 146.6 ± 51.8 N=4, t-test p>0.05). 
Since three bands are present in the mBDNF blot each band was analyzed 
individually as well as collectively and no difference was found between groups 
using either analysis method. These data supported the finding that a significant 
increase in proBDNF protein levels can be detected as soon as three hours after 
pilocarpine-induced SE and persisting for up to 24 hours, with mBDNF protein 
levels remaining constant during this same time period via western blot analysis 
utilizing an antibody that is able to probe mBDNF levels.  
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Figure 3.1: ProBDNF levels but not mBDNF levels are elevated in BDNF-
HA mice in the first 24 h after pilocarpine induced SE. 
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Figure 3.1: ProBDNF levels but not mBDNF levels are elevated in BDNF-HA 
mice in the first 24 h after pilocarpine induced SE. A) Top: Representative 
western blot (WB) run in duplicate of whole hippocampal protein homogenates 
from BDNF-HA mice sacrificed 3h after induction of SE or time-matched saline 
controls probed with anti-HA (1:3,000) and anti-actin antibodies. Middle: 
Densitometry analysis of proBDNF protein abundance. Ratio of proBDNF/Actin at 
3h after SE (n=6) expressed as percent change relative to mean values of control 
group (n=3; p<0.05). Bottom: Densitometry analysis of mBDNF protein 
abundance. Ratio of mBDNF/Actin at 3h after SE (n=6) expressed as percent 
change relative to mean values of control group (n=3; p>.05) B) Top: 
Representative WB of whole hippocampal protein homogenates from BDNF-HA 
mice probed with anti-HA (1:3,000) and anti-actin antibodies sacrificed 24h after 
induction of SE or time-matched saline controls. Middle: Densitometry analysis of 
proBDNF protein abundance at 24h post-SE. Ratio of proBDNF/Actin at 24h 
post-SE (n=6) expressed as percent change relative to mean values of control 
group (n=3; p<.005). Bottom: Densitometry analysis of mBDNF protein 
abundance. Ratio of mBDNF/Actin at 24h post-SE (n=6) expressed as percent 
change relative to mean values of control group (n=3; p>0.05). 
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Figure 3.2: proBDNF protein levels are elevated and mBDNF levels are 
unchanged in WT C57BL/6J mice after pilocarpine induced SE. A&B) 
Representative WB (bottom) and densitometry analysis (top) of whole 
hippocampal protein homogenates from WT mice sacrificed 3h (A) and 24h (B) 
after induction of SE or time-matched saline controls probed with proBDNF 
(1:1,000) and anti-actin antibodies. Ratio of proBDNF/Actin at 3h (n=5) and 24h 
(n=5) post-SE expressed as percent change relative to mean values of control 
group (n=5; p<0.0005 at 3h and p<0.05 at 24h).   C&D) Representative WB 
(bottom) and densitometry analysis (top) of whole hippocampal protein 
homogenates from WT mice sacrificed 3h (C) or 24h (D) after induction of SE or 
time-matched saline controls probed with mBDNF specific anti-BDNF (1:200) and 
anti-actin antibodies. Ratio of mBDNF/Actin at 3h (n=4) and 24h (n=4) post-SE 
expressed as percent change relative to mean values of control group (n=4; 
p>.05)  
 
To determine the cellular distribution of BDNF protein after SE, HA 
immunoreactivity was analyzed in coronal sections co-labeled with either a 
neuronal (MAP2) or astrocytic (GFAP) marker. It is important to note that the HA 
immunostaining is unable to distinguish between proBDNF and mBDNF, 
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therefore in these experiments the signal detected was considered as total BDNF 
expression. Another important limitation of these findings is that one cannot 
distinguish between HA immunoreactivity indicating the site of BDNF pre-release 
or internalization. The observed pattern of protein expression detected in control 
animals is consistent with the pattern of expression observed by others that 
previously used the same HA-tagged BDNF knock-in mice (Yang et al., 2009; 
Dieni et al., 2012). The most prominent HA immunoreactivity signal is detected in 
the mossy fiber pathway, CA3 pyramidal neurons and CA1 pyramidal neurons 
(figure 3.3a&b). When compared to controls at three hours post-SE, there is an 
increase in HA immunoreactivity as well as MAP2 immunoreactivity that can be 
detected in all hippocampal regions analyzed. The pattern of HA 
immunoreactivity is well co-localized with both MAP2 (figure 3.3a&b) and GFAP 
immunostaining (figure 3.3a&c), suggesting that within the hippocampus, BDNF 
is localized in principal neurons and astrocytes. Much immunohistochemistry 
studies performed previously utilized NeuN as a marker of neuronal nuclei to 
determine neuronal localization of HA immunereactivity. However, in order to 
determine if BDNF was trafficking in a retrograde manner, colocalization with 
MAP2 was performed.  Since much of the available tissue had been used for 
NeuN colocalization studies the MAP2 colocalization studies were limited to n=2 
for SE and n=2 for control. The pattern of HA immunoreactivity was consistent 
with the results previously obtained with the NeuN colocalization studies. Due to 
the small sample size of the groups, statistics were not applied to the data. The 
data will provide a qualitative localization of BDNF after SE.  
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Figure 3.3: BDNF protein is localized in neurons and glial cells of 
hippocampus after pilocarpine induced SE. 
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Figure 3.3: BDNF protein is localized in neurons and glial cells of 
hippocampus after pilocarpine induced SE. A) Representative confocal 
images of hippocampal subfields 3h after SE and an age- and handling-matched 
control (A; 20x mag, scale bar = 100µm) shows presence of HA immunoreactivity 
in glia, principal cells, and mossy fiber layers. The first column shows anti-HA 
(green) immunoreactivity with DAPI (blue) in each condition. The second column 
demonstrates co-localization of immunoreactivity for HA (green) and the neuronal 
marker MAP2 (red). The third column demonstrates co-localization of 
immunoreactivity for HA (green) and the glial marker GFAP (red). B) High 
magnification confocal image of CA3 hippocampal subfield (63x mag, scale bar = 
20 µm). White arrow heads correspond to neuronal localization of HA 
immunoreactivity in pyramidal cells of CA3; blue arrow heads correspond to 
localization of HA immunoreactivity in mossy fibers. (SL: stratum lucidum, SP: 
stratum pyramidale). C) High magnification confocal image of CA3 hippocampal 
subfield (63x mag, scale bar = 20 µm) demonstrating glial expression of BDNF. 
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The rapid elevation of proBDNF levels without accompanying increases in 
mBDNF detected by western blot suggests that in addition to a well-documented 
increase in BDNF expression by other groups, the normally rapid cleavage of 
proBDNF might also be impaired after SE.  Therefore, expression of enzymes 
involved in proBDNF cleavage were analyzed via western blot (n=5 for each 
group at three hours and n=4 for each group at 24 hours for all assays).  
Our analyses showed that there is no statistical difference in furin 
immunoreactivity three hours after SE (figure 3.4a; control- 100.0 ± 6.5 vs SE- 
99.9 ± 5.7; t-test p>0.05) while there is a modest but significant increase in furin 
expression at 24 hours after SE (figure 3.4b; control- 100.0 ± 2.202 vs SE- 115.1 
± 3.970; t-test p<0.05). In contrast, there is no statistical difference in the 
immunoreactivity of plasminogen observed at three (figure 3.5a; control- 100.0 ± 
5. 4 vs SE- 113.4 ± 5.0; t-test p>0.05) or 24 hours after SE (figure 3.5b; control- 
100.0 ± 11.76 vs SE- 136.8 ± 10.8; t-test p>0.05). In addition, there is no 
statistical difference in the immunoreactivity of MMP-9 observed at three (figure 
3.6a; control-100.0 ± 3.7 vs SE- 104.4 ± 3.7; t-test p>0.05) or 24 hours after SE 
(figure 3.6b; 100.0 ± 6.9 vs 112.5 ± 8.0; t-test p>0.05). Interestingly, a significant 
decrease in tPA expression was observed at both three (figure 3.7a; 100.0 ± 9.3 
vs 66.3 ± 2.4; t-test p>0.01) and 24 hours (figure 3.7b; 100.0 ± 5.9 vs 47.9 ± 2.7; 
t-test p>0.001) after SE. 
In order to further investigate the mechanism of proBDNF cleavage, the 
levels of protease inhibitors known to inhibit activity of proBDNF cleavage 
enzymes were analyzed.  
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Figure 3.4. Furin protein levels are elevated in hippocampus at 24h after pilocarpine SE.  
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Figure 3.4. Furin protein levels are elevated in hippocampus at 24h after 
pilocarpine SE. Representative western blots of whole hippocampal protein 
homogenates from WT mice sacrificed 3h (A) & 24h (B) after induction of SE or 
time-matched saline controls. Densitometry analysis of abundance of different 
cleavage proteins normalized to actin and expressed as percent change relative 
to mean values of control group. A&B anti-furin (1:1,000). The sample size for 3h 
is n=5 in each group and n=4 in each group at 24h. 
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Figure 3.5. Plasminogen protein levels are not changed in the hippocampus at three or 24h after 
pilocarpine SE.  
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Figure 3.5. Plasminogen protein levels are not changed in the hippocampus 
at three or 24h after pilocarpine SE. Representative western blots of whole 
hippocampal protein homogenates from WT mice sacrificed 3h (A) & 24h (B) 
after induction of SE or time-matched saline controls. Densitometry analysis of 
abundance of different cleavage proteins normalized to actin and expressed as 
percent change relative to mean values of control group. A&B anti-plasminogen 
(1:3,000). The sample size for 3h is n=5 in each group and n=4 in each group at 
24h. 
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Figure 3.6. MMP-9 protein levels are not changed in the hippocampus at three or 24h after pilocarpine SE.  
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Figure 3.6. MMP-9 protein levels are not changed in the hippocampus at 
three or 24h after pilocarpine SE. Representative western blots of whole 
hippocampal protein homogenates from WT mice sacrificed 3h (A) & 24h (B) 
after induction of SE or time-matched saline controls. Densitometry analysis of 
abundance of different cleavage proteins normalized to actin and expressed as 
percent change relative to mean values of control group. A&B anti-MMP9 
(1:3,000). The sample size for 3h is n=5 in each group and n=4 in each group at 
24h. In collaboration with Yasmin Cruz del Angel. 
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Figure 3.7. TPA protein levels are decreased in the hippocampus at three and 24h after pilocarpine SE.  
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Figure 3.7. TPA protein levels are decreased in the hippocampus at three 
and 24h after pilocarpine SE. Representative western blots of whole 
hippocampal protein homogenates from WT mice sacrificed 3h (A) & 24h (B) 
after induction of SE or time-matched saline controls. Densitometry analysis of 
abundance of different cleavage proteins normalized to actin and expressed as 
percent change relative to mean values of control group. A&B anti-tPA (1:1,000). 
The sample size for 3h is n=5 in each group and n=4 in each group at 24h. 
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Figure 3.8. There is no change in A2AP protein expression at three and 24h in the hippocampus after pilocarpine 
SE.  
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Figure 3.8. There is no change in A2AP protein expression at three and 24h 
in the hippocampus after pilocarpine SE. Representative western blots of 
whole hippocampal protein homogenates from WT mice sacrificed 3h (A) & 24h 
(24) after induction of SE or time-matched saline controls. Densitometry analysis 
of abundance of different inhibitor proteins normalized to actin and expressed as 
percent change relative to mean values of control group. A&B) anti-alpha2-
antiplasmin (1:2,000). The sample size for 3h is n=5 in each group and n=4 in 
each group at 24h. 
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Figure 3.9. Neuroserpin protein levels are decreased at 3h in the hippocampus after pilocarpine SE.  
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Figure 3.9. Neuroserpin protein levels are decreased at 3h in the 
hippocampus after pilocarpine SE. Representative western blots of whole 
hippocampal protein homogenates from WT mice sacrificed 3h (A) & 24h (24) 
after induction of SE or time-matched saline controls. Densitometry analysis of 
abundance of different inhibitor proteins normalized to actin and expressed as 
percent change relative to mean values of control group. A&B) anti-neuroserpin 
(1:2,000). The sample size for 3h is n=5 in each group and n=4 in each group at 
24h 
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Figure 3.10. Glycosylated 28kDa TIMP-1 protein levels are decreased at 24h in the hippocampus after 
pilocarpine SE.  
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Figure 3.10. Glycosylated 28kDa TIMP-1 protein levels are decreased at 24h 
in the hippocampus after pilocarpine SE. Representative western blots of 
whole hippocampal protein homogenates from WT mice sacrificed 3h (A) & 24h 
(24) after induction of SE or time-matched saline controls. Densitometry analysis 
of abundance of different inhibitor proteins normalized to actin and expressed as 
percent change relative to mean values of control group. A&B) anti-TIMP-1 
(1:1,000). The sample size for 3h is n=5 in each group and n=4 in each group at 
24h. In collaboration with Yasmin Cruz del Angel. 
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Figure 3.11. PAI-1 protein levels are elevated at three and 24h in the hippocampus after pilocarpine SE.  
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Figure 3.11. PAI-1 protein levels are elevated at three and 24h in the 
hippocampus after pilocarpine SE. Representative western blots of whole 
hippocampal protein homogenates from WT mice sacrificed 3h (A) & 24h (24) 
after induction of SE or time-matched saline controls. Densitometry analysis of 
abundance of different inhibitor proteins normalized to actin and expressed as 
percent change relative to mean values of control group. A&B) anti-PAI-1 
(1:1,000). The sample size for 3h is n=5 in each group and n=4 in each group at 
24h. 
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I observed no change in the immunoreactivity of A2AP, an inhibitor of 
plasmin activity, at three (figure 3.8a; control- 100.0 ± 4.8 vs SE- 110.2 ± 1.9; t-
test p>0.05) or 24 hours after SE (figure 3.8b; control- 100.0 ± 6.0 vs SE- 96.4 ± 
5.3; t-test p>0.05). A slight reduction in the immunoreactivity of neuroserpin, a 
known inhibitor of tPA activity, at three hours after SE was observed (figure 3.9a; 
control- 100.0 ± 2.2 vs SE- 72.3 ± 5.4; t-test p<0.01) but not at 24 hours after SE 
(figure 3.9b; control- 100.0 ± 2.7 vs SE- 101.0 ± 3.6; t-test p>0.05). As seen in 
figure 5e, two forms of TIMP-1, an inhibitor of MMP activity, can be detected via 
western blot, a 23kDa non-glycosylated and a 28kDa glycosylated form. There is 
no statistical difference in the immunoreactivity of the non-glycosylated form at 
three (figure 3.10a; control- 100.0 ± 6.1 vs SE- 93.3 ± 5.4; t-test p>0.05) or 24 
hours after SE (figure 3.10b; control- 100.0 ± 4.9 vs SE- 86.41 ± 3.9; t-test 
p>0.05). In addition, there is no statistical difference in the immunoreactivity of 
the glycosylated form at three hours after SE (figure 3.10a; control- 100.0 ± 7.9 
vs SE- 85.0 ± 2.6; t-test p>0.05); however, there is a significant reduction at 24 
hours after SE (figure 3.10b; control- 100.0 ± 5.0 vs SE- 65.4 ± 4.1; t-test 
p<0.01). Most notably, there is a robust increase in the immunoreactivity of PAI-
1, an inhibitor of both furin and tPA, at three (figure 3.11a; control- 100.0 ± 13.1 
vs SE- 183.8± 18.2; t-test p<0.01) and 24 hours after SE (figure 3.11b; control- 
100.0 ± 12.3 vs SE- 590.8 ± 63.3; t-test p<0.001).  
Discussion 
Several groups have previously evaluated the levels of BDNF in epilepsy 
models (Ernfors et al., 1991; Rudge et al., 1998; Altar et al., 2004; Roberts et al., 
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2006). The majority of these studies quantitatively evaluated levels of mRNA but 
did not determine the levels of proBDNF and mBDNF protein. A few studies have 
evaluated the levels of proBDNF and mBDNF after seizures but to my 
knowledge, this is the first study detecting an increase in proBDNF within 24 
hours of SE onset. Unsain et. al analyzed the levels of BDNF following 
pilocarpine-induced SE in adult rats and demonstrated an increase in proBDNF 
immunoreactivity 72 hours after SE. In addition, they observed increased 
mBDNF levels at zero, 24 and 72 hours after SE (Unsain et al., 2008). Using 
immunohistochemistry, Volosin et. al reported an increase in proBDNF and 
proNGF immunoreactivity one day after pilocarpine-induced SE in rats (Volosin 
et al., 2008). This same group recently reported increases in another 
proneurotrophin, proNGF. Elevated levels of proNGF protein were observed 24 
hours after kainic acid-induced seizures in vivo. This increase in proNGF was not 
accompanied by increases in mature NGF and resulted from inhibition of MMP-7 
by TIMP-1 (Le and Friedman, 2012). Most recently, it was reported that both 
proBDNF and mBDNF levels were elevated 24 hours after single dose 
pilocarpine SE in 129 mice (VonDran et al., 2014).   
Importantly, this work is the first to report the relative protein levels of 
proBDNF and mBDNF in hippocampus acutely after pilocarpine-induced SE. 
Since currently available commercial antibodies to the mature domain of BDNF 
do not distinguish between proBDNF and mBDNF with sufficient selectivity, 
epitope tagged knock-in mice were used for the major studies of this report.  
Utilizing this unique and sensitive genetic tool has permitted the detection of an 
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increase in proBDNF protein levels as early as three hours post-SE, with levels 
rising higher over 24 hours and with mBDNF protein levels remaining constant at 
both time points (figure 2). One potential concern in using BDNF-HA tagged mice 
to follow endogenous presence of BDNF is the possibility that the HA-tag may 
alter BDNF expression and/or processing.  This seems unlikely, however, as it 
has been previously reported that the HA-tagged BDNF is expressed in the same 
manner as WT BDNF (Yang et al., 2009, 2014). Further, the findings using the 
BDNF-HA tagged mice that were assayed with HA detection by western blot 
analysis were replicated using commercial BDNF antibodies in WT mice (figure 
3.2). The results of the studies suggest that levels of proBDNF are rapidly 
increased after SE and may mediate a large portion of the BDNF signaling in the 
first 24 hours after SE. There may be a number of reasons why the findings differ 
from those previously published, including differences in the species (rats vs 
mice), background strain (129 vs. C57BL/6J), and model of SE (kainic acid or 
single high dose pilocarpine vs repeated low dose pilocarpine). Repeating the 
studies utilizing the same techniques on different models would help determine 
the effect of model selection on the findings. The most important distinction 
between the previous studies and the one presented here, however, is the use of 
BDNF-epitope tagged knock-in mice that allowed levels of proBDNF and mBDNF 
to be probed with high sensitivity and specificity. 
To delineate the spatial expression of BDNF in response to SE, 
immunohistochemistry for HA was combined with MAP2 and GFAP staining in 
BDNF-HA tagged mice to evaluate expression in neurons and astrocytes, 
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respectively. The pattern of immunoreactivity (ir) for total BDNF in controls is 
similar to what has been previously reported by others (Dieni et al., 2012; 
VonDran et al., 2014). BDNF-ir is increased three hours after SE which 
colocalizes with MAP2 and GFAP demonstrating that proBDNF is expressed in 
principal neurons and astrocytes in all hippocampal subfields. BDNF-ir is most 
strikingly elevated in the cell bodies of principal cells of CA3 and CA1 and the 
mossy fiber pathway. Unfortunately, one is unable to determine if the BDNF 
localization is a site of pre-release or internalization. It is possible that the BDNF 
localized in the astrocytes may be due to internalization since TrkB.T1 is located 
primarily in hippocampal astrocytes. The truncated Trk receptors can function as 
a dominant-negative inhibitor by forming heterodimers with full-length TrkB 
leading to internalization of BDNF and triggering clearance of BDNF and TrkB 
(Haapasalo et al., 2002). Another interesting finding observed in the 
immunostaining studies is the increase in MAP2 immunoreactivity 3hr after SE 
when compared to controls. Increased expression of MAP2 has previously been 
reported at 1hr and 3hr after kainic acid induced-SE in P9 rats (Jalava et al., 
2007). Increased MAP2 immunoreactivity was observed in the dentate gyrus at 3 
days and peaking at 14 days after rapid hippocampal kindling in adult rats (Tang 
et al., 2014). In the adult rat pilocarpine induced SE model, an increase in MAP2 
immunoreactivity was observed at 1 and 2 weeks post-SE (Ferhat et al., 2003). A 
dramatic increase in dendritic spine density and morphological complexity is 
observed 5 hours after seizure activity induced by unilateral electrolytic lesion of 
the hilus (Bundman and Gall, 1994). In the intra-amygdala kainic acid model in 
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adult rats, an increase in MAP2 expression is observed at 4 days after SE 
(Pollard et al., 1994). The aforementioned increases in MAP2 expression 
precede and overlap with the time course of mossy fiber sprouting. It is 
hypothesized that transient enhanced expression of MAP2 and formation of 
dendritic varicosities may be either a maladaptive response to excitotoxic injury 
leading to cell death or an adaptive response leading to transient alterations in 
cytoskeletal proteins without cell death (Jalava et al., 2007). MAP2 regulates 
microtubule polymerization and stability during neuronal development thereby 
playing an important role in generation, extension, and stability of dendrites 
(Matus, 1991). An increase in MAP2 expression is correlated with sprouting and 
synaptic reorganization after injury (Kwak and Matus, 1988). Further studies 
would be needed to fully elucidate the consequences of elevated MAP2 
expression after SE.  
To identify potential mechanisms leading to prolonged elevation in proBDNF 
without a subsequent elevation in mBDNF, I examined the expression of 
cleavage machinery known to process proBDNF into mBDNF. These studies 
were based on the hypothesis that an elevation in proBDNF levels without a 
subsequent elevation in mBDNF may be due, at least in part, to a reduction in 
proneurotrophin cleavage, akin to the decrease in MMP-7 cleavage of proNGF 
reported to occur after kainic acid-induced SE in rats (Le and Friedman, 2012). 
Two potential mechanisms that could contribute to reduced proBDNF cleavage 
were identified, a significant decrease in tPA expression and a robust increase in 
PAI-1. The tPA/plasmin proteolytic machinery is a major contributor to 
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extracellular proBDNF cleavage, and PAI-1 inhibits both furin and tPA, thereby 
inhibiting both intracellular and extracellular cleavage of proBDNF. Elevation in 
levels of PAI-1 normally corresponds to depression in tPA activity. It is thought 
that elevation of PAI-1 is an adaptive mechanism to attenuate excessive tPA 
activity which can contribute to CNS pathology (Melchor and Strickland, 2005). In 
addition, theta burst stimulation (14,400 pulses, 60 min) triggers simultaneous 
release of proBDNF and tPA to generate mBDNF extracellularly in vitro 
suggesting that this could occur as a result of repeated neuronal firing as occurs 
during a seizure episode. In the same study, exogenous administration of PAI-1 
inhibited tPA activity thereby attenuated conversion of proBDNF to mBDNF. 
Inhibition of furin and proconvertase 1/3, intracellular cleavage mechanisms, with 
FIN-II had no effect on proBDNF cleavage. Taken together these data suggest 
that the major route of proBDNF conversion to mBDNF occurs extracellularly with 
PAI-1 being able to inhibit that conversion (Nagappan et al., 2009). 
The current study does not investigate the downstream consequences of 
elevated proBDNF levels following SE.  The rapid increase in proBDNF after 
onset of SE is temporally positioned to mediate BDNF-induced JAK/STAT 
activation that begins within an hour of SE onset (Lund et al., 2008).  
Interestingly, high dose proBDNF has recently been reported to lead to 
repression of GABAAR synthesis in cultured hippocampal neurons in vitro 
through activation of the JAK-STAT-ICER pathway (Riffault et al., 2014), 
suggesting that it might also mediate JAK/STAT activation and subsequent 
GABAAR α1 subunit repression in vivo after SE. Further studies are required to 
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fully understand the downstream molecular effects of the acute elevation in 
proBDNF levels demonstrated in these studies and the role of proBDNF signaling 
in epileptogenesis. 
In summary, I have demonstrated an increase in proBDNF levels that occur 
as early as three hours after SE with levels rising higher through 24 hours after 
SE. Interestingly, mBDNF levels remain constant through 24 hours after 
pilocarpine induced SE. HA immunoreactivity (indicative of total BDNF) was 
primarily observed in principal neurons and their processes, but is also seen in 
astrocytes and increases in all hippocampal subregions at three hours following 
the onset of SE. The elevation in proBDNF without subsequent increases in 
mBDNF may be due to reductions in proBDNF cleavage, which appear to be 
mediated by acute decreases in tPA expression and increases in PAI-1, an 
inhibitor of both intracellular and extracellular proBDNF cleavage. These findings 
suggest that proBDNF is highly abundant immediately following SE and may be 
the initial neurotrophin signal that drives intracellular signaling during the acute 
phases of epileptogenesis. 
Future Directions 
Evaluating pro- and mBDNF at more time points would aid in comparing 
my results to others. In addition, evaluating protease machinery in BDNF-HA 
mice would ensure that the transgene did not alter cleavage enzyme and inhibitor 
expression. A direct readout of protease activity would help directly correlate the 
results observed with activity. Since PAI-1, a known inhibitor of tPA, is elevated 
after SE, fibrin zymography would aid in determining if there is indeed a decrease 
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in cleavage activity (Kim et al., 1998). It is thought that the decrease in proBDNF 
cleavage acutely after SE is due to elevation in PAI-1 a knockdown experiment 
would be useful in determining the role PAI-1 in proBDNF cleavage in vivo. Many 
different methods could be used to knockdown PAI-1 activity including infusion of 
complimentary oligodeoxynucleotides, PAI-1 specific monoclonal antibodies 
(MA33H1), or pharmacological inhibition with a small molecule inhibitor such as 
tiplaxtinin to name a few (Berry et al., 1998; Elokdah et al., 2004). One could also 
alter cleavage by perturbing the protease either through knockdown via tPA-
STOP, a pharmacological inhibitor of tPA, or exogenous administration of tPA. 
Early experiments intended to use a cleavage resistant BDNF-HA knock-in 
mouse to elucidate the role of proBDNF signaling in epileptogenesis in the 
absence of mBDNF signaling. However, these mice were extremely difficult to 
breed and the colony was lost. Another area of interest is the role of pro-peptide 
in signaling. It is no longer thought that cleaved pro domain remains inert. An 
interesting story is swiftly emerging regarding the role of pro-peptide in 
neurotrophin signaling (Mizui et al., 2011).  
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CHAPTER IV 
THE ROLE OF PROBDNF IN EPILEPTOGENESIS IN A MOUSE MODEL 
The previous two chapters focused on mouse models of epilepsy and 
characterization of proBDNF expression after SE. My original overarching 
hypothesis theorized that BDNF processing may play an important role in post-
SE neurotrophin receptor activation thereby affecting GABAAR subunit 
expression and later development of spontaneous seizures. The research 
described in chapters II and III focused on understanding BDNF expression and 
processing after SE. Chapter II focused on developing an effective model of SE 
induction in mice. There are several advantages to using a mouse model of 
epilepsy, the most important one being the use of genetically engineered mice 
(typically C57BL/6J mice) to genetically dissect the molecular pathways that may 
be important for the development of epilepsy.  The studies described in chapter II 
demonstrated that the repetitive pilocarpine-induced SE model can be used as a 
model of TLE with some significant drawbacks, mainly efficacy. Some 
laboratories utilize a single high dose pilocarpine model, however, new batches 
of mice need to be tested at regular intervals to ensure equivalent 
chemoconvulsant sensitivity. The repetitive pilocarpine model bypasses this 
difficulty by dosing each animal individually thereby reducing the effects of intra-
animal variability in chemoconvulsant sensitivity. After several years of 
refinement, the repetitive pilocarpine model was effective in inducing SE in 
approximately 25-50 percent of animals. Consistency remained the most difficult 
challenge to successful adoption of the method. There would be experimental 
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days where only one or no animals progressed into and survived SE. Therefore 
studies were conducted to optimize a more consistent mouse model of TLE, 
intrahippocampal kainic acid. The intrahippocampal kainic acid model provided 
strong SE with a protracted latent period lasting about three weeks, with all of the 
animals going on to develop spontaneous electrographic seizures. As with all 
chemoconvulsant models, the dose of chemoconvulsant remains one of, if not 
the most important, variable to optimize. Typically the dosage is optimized to 
provide the lowest level of mortality with the highest level of damage in order to 
compress the time course of epileptogenesis. However, this compression may 
not be the best course of action. By doing so, we could be missing biological 
processes that would otherwise be observed in a more protracted latent period.  
 With so much variability observed in the outcomes of epilepsy models 
between laboratories, a multi-center collaboration was set up under the Epilepsy 
Microarray Consortium to combat such variability in 2002. The group led by Dr. 
Raymond Dingledine grew out of the NINDS-sponsored workshop on 
microarrays and involves seven institutions in the United States and Europe 
(Lowenstein, 2008). The consortium combined data from multiple models of 
epileptogenesis and different labs in order to determine the genetic regulation of 
epilepsy development. Since the same model is used by different labs and the 
samples are analyzed by another blinded laboratory, the data obtained is 
irrespective of animal model or intra-laboratory variation.  These studies have 
been limited to DNA microarrays but a similar collaboration utilizing reverse-
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phase protein arrays or protein phosphorylation would provide significant 
advances in our understanding of receptor signaling pathways activated after SE.  
 The whole point of developing animal models of epilepsy is to further our 
understanding of human epilepsies. However, one must keep in mind that no 
animal model will recreate a human model of epilepsy exactly. One of the major 
roadblocks in modeling epilepsies is the heterogeneous nature of the epilepsies 
in question. Approximately thirty percent of patients are diagnosed with a 
pharmacoresistant form of epilepsy. These are the patients we should be 
focusing our efforts on. However, this thirty percent of patients contain within it 
countless etiologies with various sequelae. Many are often referred to as 
cryptogenic or of unknown cause, making them challenging to model, which 
could lead to failed therapeutic efforts or the “Lost in Translation” phenomenon.  
The heterogeneity of the patient population makes modeling a daunting 
task. Every year there are heated debates between researchers and clinicians 
questioning the utility of animal models and which is the best animal model. It is 
important to remember why animal models are used in the first place - to further 
our understanding of epilepsy while providing an avenue to test hypotheses. It 
seems very unlikely that a disease as multifactorial as epilepsy can be 
recapitulated by a single model. In patients, our understanding of their disease 
and prognosis rests on their etiology. Therefore, it is important to refer to our 
findings in the context of the animal model used to obtain those findings. Many 
changes occur in the brain after an injury that can lead to development of 
epilepsy, many of which are described in chapter I. It was thought that mossy 
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fiber sprouting yielded recurrent circuits that led to hyperexcitability. However, 
recently this closely held dogma has been called into question since Buckmaster 
and colleagues prevented mossy fiber sprouting, which yielded no change 
frequency of spontaneous seizures in pilocarpine-induced SE mice (Buckmaster 
and Lew, 2011; Heng et al., 2013). These data cast doubt on the recurrent 
excitation hypothesis of temporal lobe epilepsy. Even cell death has been shown 
to not be necessary for development of spontaneous seizures (Raol et al., 2003). 
Significant interest has been generated in understanding other changes that 
occur after epileptogenic injury including the role of molecular signaling 
pathways, inflammation, bioenergetics, and epigenetics to name a few.  
The field is poised for considerable expansion in knowledge. With each 
study the mechanisms that are important for epileptogenesis are coming to light 
and those that are not essential are being revealed. Even though the relevance 
of cell death and mossy fiber sprouting has been called into question other 
mechanisms have been shown to be important for epileptogenesis. One example 
is loss of inhibitory neurons. Loss of GABA neurons has been found in nearly all 
models of acquired epilepsy, including SE, TBI, and kindling models (Sloviter, 
1987; Lowenstein et al., 1992; Schwarzer et al., 1995; Buckmaster and Dudek, 
1997; Gorter et al., 2001). Loss of inhibitory somatostatin and GABA neurons is 
observed in the dentate hilus in human TLE (de Lanerolle et al., 1989; Robbins et 
al., 1991; Mathern et al., 1995; Sundstrom et al., 2001; Swartz et al., 2006). 
Interestingly, GABA neuron transplantation into the hippocampus of adult 
pilocarpine induced SE mice was able to reduce the reduce seizure frequency by 
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92 percent with 50 percent of the implanted mice exhibiting no electrographic 
seizures over the 7-10 day course of video-EEG monitoring (Hunt et al., 2013). 
The various animal models of TLE possess a significant degree of heterogeneity 
in terms of biological and neuropathological processes that lead to 
epileptogenesis much like the heterogeneity observed in human TLE. Therefore, 
it is important to keep in mind the limitations and advantages of each model and 
interpret any findings in the context of the model used with findings that are 
consistent across different models being stronger candidates for therapeutic 
intervention. 
Many of the pharmacological agents used in treating epilepsy today were 
screened using acute-seizure animal models prior to testing in humans. These 
anti-seizure models proved to be easy to perform, time- and cost-efficient, and 
predictive of clinical activity (Löscher and Schmidt, 2011). The traditional 
screening protocol of maximal electroshock was developed in 1946 and is used 
today to screen for drugs that are active against partial seizures (Toman et al., 
1946). However, this test has failed to detect several of the most effective drugs 
including levetiracetam and vigabatrin (Löscher, 2011). Therefore, it is important 
to perform drug screening with many different models with greater focus on 
epilepsy models as opposed to acute seizure models.  
 Chapter III characterized the expression of proBDNF and mBDNF acutely 
after pilocarpine-induced SE in C57BL/6J mice. Our laboratory along with our 
collaborators obtained compelling evidence that the alteration in GABAA α1 
subunit expression was at least in part mediated through p75NTR receptor 
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activation. Proneurotrophins are the high-affinity ligand for p75NTR and in vitro 
studies had identified these changes to be mediated by proBDNF signaling. 
Many in vitro findings do not translate well in vivo, therefore a sensitive and 
specific method was developed to evaluate the relative levels of proBDNF and 
mBDNF in vivo. The commercial antibodies available for BDNF at the time were 
quite crude and non-specific. Therefore, a collaboration was initiated with Dr. 
Barbara Hempstead at Weil-Cornell to utilize their newly developed HA-tagged 
BDNF mice. Subjecting these mice to a repetitive pilocarpine model of SE 
allowed sensitive and specific analysis of proBDNF and mBDNF protein levels 
after SE. A marked increase in proBDNF protein levels with unchanged levels of 
mBDNF was observed in the hippocampus via western blot using two different 
methods. This result was received with much controversy by the field at the 
American Epilepsy Society annual meeting, since some believe that proBDNF is 
cleaved immediately after secretion. Other groups had observed increases in 
mBDNF at later time points in other models of epilepsy. Due to the skepticism, 
another method was utilized to confirm the observations since two antibodies 
were developed during the course of the studies. The studies with the newly 
developed antibodies confirmed the elevation in proBDNF without subsequent 
increase in mBDNF in C57BL/6J mice after repetitive pilocarpine-induced SE. 
These findings differ from those of our collaborators who reported that both 
proBDNF and mBDNF levels were elevated 24 hours after single dose 
pilocarpine SE in 129 mice and rats (VonDran et al., 2014). Others have shown 
an increase in mBDNF at 24hr and both proBDNF and mBDNF at 72hr after 
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pilocarpine induced SE in rats (Unsain et al., 2008). These differences may be 
reflective of model differences in neurotrophin regulation. Not only is the time 
course of proBDNF elevation after pilocarpine different between C57BL/6J mice 
(chapter III), 129 mice (VonDran et al., 2014), and rats (Volosin et al., 2008) 
localization also differs. BDNF is localized in C57BL/6J mice (chapter III) and rats 
(Volosin et al., 2008) in neuronal bodies, mossy fibers, and astrocytes whereas in 
129 mice BDNF is localized in mossy fibers and microglia after pilocarpine 
(VonDran et al., 2014). Although the localization and time course of mBDNF and 
proBDNF expression after SE varies across different models this does not refute 
the importance of neurotrophin signaling in epileptogenesis.  
The acute elevation in proBDNF was quite striking but an important 
question remained, why is proBDNF not cleaved to mBDNF? Further studies 
brought to light a possible mechanism. Levels of cleavage enzymes and 
inhibitors were probed via western blot and a significant decrease in tPA and 
significant increase in PAI-1 was observed. Exogenous PAI-1 administration was 
sufficient to attenuate proBDNF cleavage in neuronal cultures subjected to theta 
burst stimulation (Nagappan et al., 2009). Therefore, a decrease in activity of the 
tPA/plasmin cleavage cascade by SE-induced expression of PAI-1 could be the 
mechanism of proneurotrophins cleavage inhibition observed in this model. 
Further studies would need to be conducted to verify decreased cleavage 
activity.  
 The field of proneurotrophins has been riddled with skepticism ever since 
their existence was first reported. One of the greatest challenges came from the 
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laboratory of Yves-Alain Barde, the discoverer of BDNF, who demonstrated that 
neurons secrete mBDNF and not proBDNF (Matsumoto et al., 2008). The 
following year, Barbara Hempstead published a report of proBDNF secretion 
from mouse neurons (Yang et al., 2009). These opposing findings led to 
significant debate in the field of neurotrophins (Barker, 2009). The studies of the 
Hempstead group utilized the same BDNF-HA mice that were used in the studies 
reported here. One of the most important differences that allowed observation of 
proBDNF secretion was the use of primary cultures that were free of glia with the 
studies conducted in the presence of a plasmin inhibitor, A2AP. More recently, 
the Barde group has determined that BDNF and its pro-peptide are located in 
large dense core vesicles in excitatory presynaptic terminals located in the CA1 
stratum radiatum and Schaffer collateral axons originating from BDNF-positive 
CA3 neurons and the mossy fiber pathway in the adult mouse hippocampus. The 
studies go on to challenge the classical understanding of BDNF release at 
dendrites through activity-dependent mechanisms, thereby providing evidence 
for anterograde mode of action of BDNF in vivo (Dieni et al., 2012). Once again 
the Barde group emphasized the low abundance of proBDNF and stated that 
proBDNF antibodies primarily detect the pro-peptide rather than uncleaved 
proBDNF. Fortunately, the hemeagglutinin tag is on the C-terminus of the murine 
coding exon of BDNF in the BDNF-HA mice; therefore, the N-terminal cleaved 
pro-peptide would not contain the tag (Yang et al., 2009). The functional role of 
the pro-peptide is just starting to be elucidated and may play an important role in 
long-term depression (LTD) and BDNF-mediated LTP (Mizui et al., 2011).  
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 The field of BDNF signaling is filled with interesting nuances. A single 
gene product is able to be differentially trafficked and produce a peptide that can 
activate seemingly opposing molecular pathways all through regulation of post-
translational processing. Many have referred to this concept as the “yin and 
yang” of neurotrophin signaling (Lu et al., 2005). Classically it is understood that 
proBDNF regulates neuronal apoptosis through activation of p75NTR and sortilin 
(Teng et al., 2005), whereas mBDNF regulates plasticity and cell survival through 
activation of TrkB (Cunha et al., 2010). 
 There is a significant correlation between intellectual and developmental 
disabilities and epilepsy (Brooks-Kayal, 2011). Many of these patients have 
difficulties with learning and memory. Many of the epilepsy animal models also 
possess cognitive dysfunction in a subset of animals. The cognitive dysfunction 
observed in these models could be due to altered synaptic plasticity. ProBDNF 
and mBDNF are known to play an important role in two forms of synaptic 
plasticity, LTD and LTP, respectively (Patterson et al., 1996; Woo et al., 2005; 
Leal et al., 2014). Once again the seemingly opposing nature of proBDNF and 
mBDNF make it an ideal regulator of the cellular processes that underlie 
cognition and other complex behaviors possibly those characterized as 
comorbidities of epilepsy.  
 Since activation of p75NTR is most commonly associated with neuronal 
apoptosis, it begs the question, what is the importance of cell death in epilepsy? 
The relationship between seizures, neuronal death, and epilepsy remains one of 
the most disputed topics in all of translational neuroscience (Dingledine et al., 
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2014). Many reviews and book chapters have been devoted to this subject; 
therefore, this discussion will be brief. There exists many mechanisms of seizure-
induced neuronal injury including apoptosis, autophagy, phagoptosis, pyroptosis, 
necrosis, and necroptosis. The cell types that are killed include glutamatergic 
principal neurons, and subpopulations of GABAergic interneurons. Two 
competing hypotheses exist to explain the role of neuronal death in epilepsy. 
First, maladaptive new circuits form to replace synapses lost during neuronal 
death termed the “recapitulation of development” hypothesis. The newly 
emerging second hypothesis states that the pathways upstream of cell death 
signals might contribute to epileptogenesis, which is referred to as the “neuronal 
death pathway” hypothesis. The neuronal death pathway hypothesis takes into 
consideration that not all models of epilepsy undergo significant neuronal death 
yet still go on to develop spontaneous seizures (Raol et al., 2003). Activation of 
p75NTR by proBDNF has recently been linked to modulation of GABAergic 
neurotransmission. ProBDNF triggers endocytosis and degradation of 
internalized receptors via the RhoA-Rock-PTEN pathway by decreasing GABAAR 
phosphorylation. ProBDNF also represses GABAAR synthesis through the JAK-
STAT-ICER pathway. Taken together the effect of proBDNF on epileptogenesis 
may be mediated by neuronal injury and through modulation of GABAergic 
neurotransmission. 
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Future Directions: Determine the Role of Cell-Specific p75NTR Activation on 
GABAAR Expression After SE and in Epileptogenesis 
ProBDNF possesses the ability to activate p75NTR and TrkB to a lesser 
degree. P75NTR is expressed in both neurons and glia in the dentate gyrus 
(Dougherty and Milner, 1999), therefore it is important to tease out the cell-
specific contribution of p75NTR activation after SE. I propose to use a cell-specific 
inducible knockdown of p75NTR to dissect the cell specific contribution of p75NTR 
activation to GABAR subunit expression, epileptogenesis, and neuronal cell 
death. Transgenic mice containing a floxed p75NTR gene (p75NTR-FX/FX) have been 
generously donated by Dr. Brian Pierchala and mice containing a floxed STAT3 
gene (Stat3) would be obtained from Jackson Laboratories (B6.129S1-
Stat3tm1Xyfu/J to be bred on to a congenic C57BL/6J strain). Both strains of 
floxed mice are on C57BL/6J backgrounds, homozygous for the floxed allele and 
are viable, fertile, normal in size and do not display any gross physical or 
behavioral abnormalities (Moh et al., 2007; Bogenmann et al., 2011).  When 
these mutant mice are bred to mice that express Cre recombinase, resulting 
offspring will have exons 4-6 (encoding the transmembrane and all cytoplasmic 
domains) of p75NTR or exons 18-20 (encoding the SH2 domain) in Stat3 deleted 
in cre-expressing tissues. Mating would be set up with a transgenic mouse with 
promoter driven expression of a tamoxifen regulated form of cre-recombinase 
(ERT2-cre) with either a human glial fibrillary acidic protein promoter - GFAP-
cre/ERT2 (to target astrocytes), a CamKII promoter - Camk2a-cre/ERT2 (to 
target hippocampal principal neurons) or a human ubiquitin C promoter - UBC-
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cre/ERT2 to obtain widespread expression (see figure 3.12). The specific lines 
used would be as follows: Tg(Camk2a-cre/ERT2)2Gsc from Dr. Günther Schütz 
of the German Cancer Research Center in Heidelberg, Germany (breeding pairs 
being sent by Rick Huganir at Johns Hopkins); B6.Cg-Tg(GFAP-
cre/ERT2)505Fmv/J and B6.Cg-Tg(UBC-cre/ERT2)1Ejb/J available from 
Jackson Laboratories, p75NTR-FX/FX mice from Dr. Brian Pierchala at University of 
Michigan, and B6.129S1-Stat3tm1Xyfu/J from Jackson Laboratories. Expression 
of cre recombinase will be induced by tamoxifen i.p. administration with 100uL of 
20mg/mL tamoxifen dissolved in a vehicle oil every day for five days to induce 
recombination beginning seven days prior to intrahippocampal kainic acid 
injection (figure 3.12).  
 
Figure 4.1: Tamoxifen induced cre recombination will result in cell specific 
or widespread (global) loss of the target genes p75NTR or Stat3. 
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Expression of cre recombinase will be induced by tamoxifen i.p. 
administration with 50-100uL of 20mg/mL tamoxifen dissolved in a vehicle oil 
every day or every other day for up to ten days to induce recombination. The 
GFAP-p75KO, Camk2a-p75KO, GFAP-STAT3KO, and Camk2a-STAT3KO mice 
would be compared to the wildtype non-floxed littermates to dissect the effect of 
cell specific inactivation of p75NTR and STAT3 at the time of SE on GABAR 
subunit expression, epileptogenesis, neurogenesis, and neuronal cell death. 
Separate cohorts of mice would be sacrificed at one and two weeks after 
intrahippocampal kainic acid SE and perfused for histological analysis. The 
following staining would be performed according to published methods: Fluro-
Jade B staining (Histochem-Inc) to assess degenerating cells (Bouilleret et al., 
1999; Schmued and Hopkins, 2000), Ki67 immunostaining (Vector Laboratories) 
to assess neurogenesis (Murphy et al., 2012), GFAP immunostaining (Sigma-
Aldrich) to assess astrogliosis (Bouilleret et al., 1999). A subset of mice would be 
injected with BrdU (Sigma; 150 mg/kg i.p. twice daily) on day 4, 6 and 8 after SE 
and BrdU staining (Roche) performed at the 2 week time point according to our 
published methods (Porter et al., 2004). Colocalization immunohistochemistry 
would be used to determine the degree of knockdown of p75NTR and STAT3 in 
each of the respective cell types (GFAP for astrocytes and NeuN/MAP2 for 
hippocampal neurons). In order to determine the effect of neuronal or astrocytic 
knockdown of p75NTR and STAT3 on GABAR subunit expression, animals in 
each of the groups would be sacrificed at 6 hrs, 1, 7, and 30 days after SE and 
analyzed for p75NTR, Gabra1, STAT3, and ICER mRNA levels via RT-PCR and 
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for proteins levels of p75NTR, pSTAT3, STAT3, and GABAR α1 via WB. If one 
wanted to look at gene regulation with an unbiased approach as opposed to 
analyzing candidate genes RNA-Seq would be a useful method to evaluate the 
cell-specific role of p75NTR and STAT3 in epileptogenesis on the whole 
transcriptome, which has proposed for the laboratory’s next grant proposal. The 
mice would also be monitored via long-term video-EEG to determine the effect of 
cell-specific or global knockout of p75NTR and STAT3 on epileptogenesis.  
Taken together these studies would help elucidate the role of proBDNF 
cleavage and signaling in a mouse model of epileptogenesis. 
Concluding Remarks  
As with any scientific endeavor this project has led to more questions. This is 
the first report of proBDNF expression being elevated acutely after repetitive low 
dose pilocarpine in C57BL/6J mice. The phenomenon may be caused by an 
inhibition in the tPA/plasmin cleavage cascade by PAI-1. The elevation in 
proBDNF acutely after SE may play an important role in altered GABAA signaling 
or cell death, both important seqeulae of epileptogenic injury.  
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